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INTRODUCTION 
 Medicinal plants are major parts of traditional systems in developing countries. 
Herbal medicine is defined as the branch of science in which plant used formulations are used 
to alleviate the diseases. It is known as botanical medicine or phytomedicine. Many 
infectious diseases are known to be treated with herbal remedies throughout the history of 
mankind. Even today plant materials continue to play a major role in primary health care as 
therapeutic remedies in many developing countries1. Medicinal plants which form the 
backbone of traditional medicine have in the last few decades have been the subject of very 
intense pharmacological studies. 
 Ayurvedha, Siddha, Unani and Folk medications are the main systems of indigenous 
drugs. Researchers are providing evidence and research, in validating efficacy and safety of 
utilizing traditional awareness for health and healing. 
 Medicinal plants are of great economic importance in the Indian subcontinent. The 
documentation of traditional knowledge especially on the medicinal uses of plants in the 
history has provided many important drugs of the modern day2. Even today, this area holds 
much more hidden treasure as almost 80% of the human population in developing countries is 
dependent on plant resources for healthcare3. Herbal medicines offer conventional treatments, 
providing safe and well-tolerated remedies for chronic illness which typically resulted from 
the combinations of secondary plant metabolites that are synthesized and deposited in 
specific parts or in all parts of the plant. Since, many of the existing synthetic drugs cause 
various side effects, drugs synthesized from the higher plants continue to occupy an 
important niche in modern medicine and play an important role in modern medicine and 
introduction of new therapeutic agents. 
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1.1 Advantages of Herbal Medicine: 
 Herbal medicines have long history of use and better patient tolerance as well as         
acceptance. 
 Medicinal plants have a renewable source, which is our only hope for sustainable 
supplies of cheaper medicines for the world growing population. 
 Availability of medicinal plants is not a problem especially in developing countries 
like India having rich agro-climatic, cultural and ethnic biodiversity. 
 The cultivation and processing of medicinal herbs and herbal products is 
environmental friendly. 
 Prolonged and apparently uneventful use of herbal medicines may offer testimony of 
their safety and efficacy. 
Throughout the world, herbal medicine has provided many of the most potent medicines to 
the vast arsenal of drugs available to modern medical science, both in crude form and as a 
pure chemical upon which modern medicines are structured
4
. 
 Urolithiasis is one of the most common diseases of the urinary tract which has been 
afflicting human kind since antiquity. Urinary stones affect 10-30% of the population in 
industrialized countries. It occurs more frequently in men than women but rare in children
5
. 
Urolithiasis is associated with calculus formation at any level in the urinary collecting 
system, but calculus often arises in the kidney. Recurrent stone formation is probably the 
most important problem in the after care patients who have undergone operations for renal 
and ureteric calculi. Urolith formation is a multifactorial process which may relate to diet, 
urinary tract infection, altered urinary solutes and colloids, decreased urinary drainage and 
urinary stasis, prolonged immobilization, Randall’s plaque and microliths etc6., 
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 When the urea-splitting organisms infect the urinary tract, bacteria disintegrate the 
urea excreted in urine in the presence of urease enzyme, which subsequently trigger the 
formation of ammonia rendering the urine alkaline. In alkaline state, urine leads to contain 
precipitated crystals of calcium oxalate, magnesium phosphate and calcium carbonate in large 
amount thereby leading to a strong tendency to form calculi. Bacterial infection may induce 
stone formation by crystal adherence. Most of the urea-splitting organisms belong to species 
Proteus but, organisms such as Pseudomonas, Staphylococcus, Escherichia coli and even 
Mycoplasma were reported to be capable of producing urease
7
. 
 Infected stones were associated with the organisms like E.coli, Proteus species, 
Streptococcus, Staphylococcus, Pseudomonas and Ureaplasma urealyticum
8
. There are 
increasing evidence that have been reported that the end products of urealysis damage the 
glycosaminoglycon layer of the renal urolithial cells thus leading to the bacterial adherence, 
biofilm formation and mineral encrustation. Exhaustive microbiological investigations are 
therefore necessary to diagnose and treat the infection responsible for the stone formation. 
 Urinary tract stone disease has been documented historically as far back as Egyptian 
mummies
9.
 The experimental intoxication induced by ethylene glycol is widely used for 
kidney stone formation in rats. When ethylene glycol is metabolized by the body, it produces 
toxic metabolites like glycoaldehyde, glycolate and glyoxylate. These metabolites cause 
tissue destruction, primarily from calcium oxalate deposition and metabolic abnormalities, 
specifically a high anion-gap metabolic acidosis, lactic acidosis and hypocalcemia. Oxalic 
acid combines with calcium to form calcium oxalate crystals, which deposit in the kidneys. 
This can result in hematuria and proteinuria, increased creatinine and renal failure
10
. 
 Surgical operation, lithotripsy and local calculus disruption using high power laser are 
widely used to remove the calculi. Many remedies have been employed since ages to treat 
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renal stones and most of them were from plants and proved to be useful. In Ayurvedha and 
Folklore medicine many herbs are used in management of urolithiasis
11. 
 
Azima tetracantha Lam. (Family: Salvadoraceae) locally known as “Mulsangu”, is a 
scrambling spinous shrub flowering throughout the year found in Peninsular India, West 
Bengal, Orissa, African countries and extends through Arabia to tropical Asia. The leaves of 
the plant are elliptical in shape and are rigid, pale green coloured. The flowers are small, 
greenish white (or) yellow coloured, unisexual in axillary fasciles. The berries are white in 
colour, usually one seeded and edible. The plant is considered as a powerful diuretic and also 
used to treat rheumatism, dropsy, dyspepsia, chronic diarrhea and as a stimulant tonic for 
women after confinement. 
 It also possesses anti-inflammatory, anti-pyretic and analgesic activity. The plant 
shows potent antibacterial and antifungal activity. However, till the date there have been no 
investigations supporting the anti-urolithiatic properties of this plant. Hence, this study has 
been taken with an aim to evaluate the anti-urolithiatic potential of Azima tetracantha Lam. 
extract in in-vivo ethylene glycol model. 
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AIM & OBJECTIVE 
 
 To identify the active phytochemical components in the whole plant extract of Azima tetracantha
 
 To determine the Calcium oxalate crystallization inhibition by in-vitro method. 
 
 To investigate the in-vivo anti urolithiatic effect of various extract of Azima tetracantha Lam. 
in Ethylene glycol induced urolithiasis in Wistar albino rats. 
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REVIEW OF LITERATURE 
3.1 PLANT PROFILE 
Plant name: Azima tetracantha Lam.  
Synonym: Monetia barlerioides 
TAXONOMY 
Kingdom: Plantae  
Division: Magnoliophyta 
Class: Magnoliopsida 
Sub-class: Dilleniidae  
Order: Brassicales 
Family: Solvadoraceae 
Genus: Azima 
Species: tetracantha 
VERNACULAR NAMES12 
Tamil: Mulsangu 
Kannada: Uppimullu 
Ayurvedic medicine: Kundali 
 Malayalam: Esanku 
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Azima tetracantha Lam. 
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English: Needle bush 
DISTRIBUTION 
Azima tetracantha Lam. is a scrambling spinous shrub or small tree of about 5 m 
flowering throughout the year found in Peninsular India, West Bengal, Orissa, African 
countries and extends through Arabia to tropical Asia. 
PARTS USED 
Whole plant 
DESCRIPTION 
Stem: Bark green on younger branches, turning brown, young twigs sometimes 
square in cross-section, hairy; characteristic whorls of four long straight spines occur along 
the length of branches at each of the leaf axils. 
Leaves: Oval to circular, opposite or nearly so, each pair at right angles to the 
previous and following one; light green, leathergy and usually hairy; apex has a sharp tip, 
margin entire, tapering at both ends, short petiole. 
Flowers: Dioecious; light green or yellow, small flower clusters in axils; floral parts 
in fours; petals recurving, calyx bell-shaped. 
Seed/Fruit: Round berry of 1cm diameter with a sharp apical tip; fleshy, light 
colored, containing one or two seeds; ripe from summer into the next winter. 
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CHEMICAL CONSTITUENTS(13,14,15) 
The plant contains alkaloids, flavonoids, sterols, terpenoids, volatile oil and fatty 
acids, saponins. 
 A number of chemical constituents have been reported from the leaves 
(Friedelin, Lupeol, Glutinol and beta-sitosterol), the seed oils (fatty acids such as myristic 
acid, palmitic acid, stearic acid, arachidic acid, oleic acid, linoleic acid, eicosenoic acid and 
flavonoids), the seed, root, stem and young leaves (N-methoxy-3-indolyl methyl-
glucosinolate), roots and the leaves (terpenoids) also the dimeric pipperidine alkaloids 
azimine, azcarpine and carpaine are present in all plant parts. 
 MEDICINAL USES 
 The juice of the leaves is used to relieve the cough phthisis and asthma. 
 In western India juice of the leaves is applied as eardrops against ear ache and 
crushed leaves placed on painful teeth. 
 In India and Sri Lanka the root, root bark and leaves are administered with 
food as a remedy for rheumatism. 
 The plant is considered as a powerful diuretic and also used to treat dropsy, 
dyspepsia, chronic diarrhea and as a stimulant tonic for women after 
confinement. 
 The leaves of this plant possess anti-inflammatory, anti-ulcer and analgesic16 
activity. 
 This plant possesses anti-bacterial and anti-fungal properties. 
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3.2 PLANT REVIEW: 
Antimicrobial activity 
Gayathri G et al., in 2011 revealed that methanolic extract of Azima tetracantha 
Lam. leaves possess greater antimicrobial activity than chloroform extract. The test extracts 
showed percent inhibition in a concentration dependent manner against the test organisms 
such as S.aureus, P.vulgaris etc17. 
Hema et al., in 2012 revealed that the antimicrobial activity of leaves of the 
medicinal plant Azima tetracantha Lam. collected from the regions of Ambalathara, Kerala, 
South India was checked against the clinical pathogens by agar well diffusion method. Azima 
tetracantha Lam. showed highest antimicrobial activity on ethanolic extracts. Antimicrobial 
activities of five solvent extracts (ethanol, methanol, acetone, chloroform and distilled water) 
were tested against seven clinical pathogens such as Staphylococcus aureus (Pus), Klebsiella 
sp. (Sputum), Escherichia coli (Urine), Serratia sp. (Sputum) and Proteus sp. (Sputum). 
Among the five solvents tested, ethanolic extracts of Azima tetracantha Lam. showed higher 
significant activity against the pathogenic organisms18. 
Antibacterial activity of Azima tetracantha Lam. and phytochemicals separated from 
Azima tetracantha Lam. were alkaloids, flavanoids and sterol and were tested against 
Staphylococcus aureus, Bacillus subtiles, Klebsiella pneumonia, Pseudomonas aeruginosa 
and E.coli (Gowthami et al., 2012). The sterols compound exhibited maximum zone of 
inhibition against Bacillus subtilis (25mm) and Pseudomonas aeruginosa (24mm). The 
alkaloid compound showed minimum zone of inhibition was observed in Bacillus subtilis 
(12mm) and Pseudomonas aeruginosa (12mm). Maximum zone of inhibition was observed in 
sterols compound when compared with alkaloids and flavonoids19. 
The study designed by Duraipandyan et al., in 2011 evaluated the antifungal activity 
of Azima tetracantha Lam. Extracts and isolated compound (friedelin) against fungi. 
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Antifungal activity was carried out using broth microdilution method and fractions were 
collected using (silica gel) column chromatography. The antifungal activity of Azima 
tetracantha Lam. crude extracts and isolated compound (friedelin) were evaluated using the 
microdilution method. Hexane extract showed some antifungal activity. The results suggested 
that Friedelin is a strong antifungal agent20. 
Anti-inflammatory, analgesic and antipyretic effects of friedelin isolated from Azima 
tetracantha Lam. 
Paulrayer et al., in 2011 revealed the effects of friedelin on inflammation were 
studied by using carrageenan-induced hind paw oedema, croton oil-induced ear oedema, 
acetic acid-induced vascular permeability, cotton pellet-induced granuloma and adjuant-
induced arthritis. The analgesic effect of friedelin was evaluated using the acetic acid-induced 
paw liking response and the hot-plate test. The antipyretic effect of friedelin was evaluated 
using the yeast-induced hyperthermia test in rats. 
In the acute phase of inflammation, maximum inhibitions were noted with friedelin in 
carrageenan-induced ear oedema. Administration of friedelin significantly decreased the 
formation of granuloma tissue. Friedelin also produced significant analgesic activity in the 
acetic acid-induced abdominal constriction response and formalin-induced paw licking 
response. Treatment with friedelin showed a significant dose-dependent reduction in pyrexia 
in rats21. 
The results of the study made by Nargis Begum T et al., in 2011 suggest that the 
ethanolic leaf extract of Azima tetracantha Lam. in doses of 100 and 200 mg/kg, significantly 
reduce the temperature of pyretic rats as revealed from the observation that the average 
percentage of antipyretic activity increased with the concentration of the extracts (200 mg/kg) 
compared with the control22. 
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Antioxidant and free radical scavenging activities of Azima tetracantha Lam. leaf 
extracts 
Yildrim et el., in 2000 confers the antioxidant effect of Azima tetracantha Lam. leaf 
extracts. Phenolic compounds are typical active oxygen scavengers in plants and are known 
to contribute directly to antioxidant action. The results indicate a high concentration of 
polyphenols in the leaves of Azima tetracantha Lam.. The hydroxyl groups of the phenolic 
compounds confer the scavenging ability of the plant. The decrease in absorbance of DPPH 
radical is due to its reduction by different antioxidants, which in turn indicates the free radical 
scavenging property of the leaves of Azima tetracantha Lam23. 
The studies conducted by Siriwardhana et al., (2003) reported a high correlation 
between DPPH radical scavenging potential and total phenolic content24. 
The reducing capacity of a compound may also serve as a significant indicator of its 
potential antioxidant activity25 (Sreekanth et al., 2003, Leskovar et al., 2004). 
In a study done by Gayathri G et al., in 2011, the reducing capacity increased with 
increasing concentration of the plant extract. This shows that the antioxidant compounds can 
react with increasing concentration of the plant extract. This shows that the antioxidant 
compounds can react with free radical to convert them to more stable products and thereby 
terminate radical chain reactions17. 
Thendral et al., in 2010 revealed that Azima tetracantha Lam. leaves were proved to 
be good source of natural phenolic compounds. The methanolic extract of the leaves showed 
better free radical capacity against different reactive oxygen/nitrogen species, among other 
extracts although with different efficiencies. The high content of antioxidants like phenolic 
compounds, flavonoids and vitamins found in these extracts, may impart health benefits by 
combating the free radicals in synergistic manner along with other compounds and thus 
constitute part of the basis for the ethno pharmacological claim26. 
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According to Maruthi T Ekbote et al., in 2010, the ethanolic extract of Azima 
tetracantha leaves exhibited a significant antioxidant effect showing increased levels of 
enzymatic and non-enzymatic parameters, viz. catalase, GSH, total thiols and decreased level 
of malondialdehyde30. 
Antinephrotoxic potential of Azima tetracantha Lam 
The biochemical markers of nephrotoxicity are urea, creatinine and GGT. Their levels 
are significantly elevated in nephrotoxic condition due to metal induced damage to nephrons. 
In nephrotoxicity, the serum urea and creatinine accumulates because the rate of serum urea 
and creatinine production exceeds the rate of clearance due to defects in the glomerular 
filtration rate. The results of the study done by Manikandanselvi et al., in 2012 shows the 
significant elevation in the levels of urea, GGT and creatinine in ferrous sulphate induced 
group compared to control. After treatment with herbal drug viz, Azima tetracantha Lam. 
There was a significant decrease in the levels near to normal compared to ferrous sulphate 
induced group27. 
Antiulcer activity of Azima tetracantha Lam 
Muthusamy et al., in 2009 reveals that ethanolic extract of Azima tetracantha Lam.  
showed significant dose-dependent ulcer protective effect against cold restraint stress and 
aspirin plus pylorus ligation induced gastric ulcers. The gastro duodenal ulcer protecting 
effect of ethanolic extract of Azima tetracantha Lam.  may be due to its predominant effect 
on the mucosal defensive factors rather than offensive factors28. 
Hepatoprotective activities of Azima tetracantha Lam 
Reports documented by Nargis et al.,in 2011 reveals that the rats treated with 
ethanolic extract of Azima tetracantha Lam. showed a significant reduction in all the five-
biochemical parameters of liver damage (AST, ALT,ALP,ACP and total bilirubin) elevated 
by carbon tetrachloride. Ethanolic leaf extract treatment of Azima tetracantha Lam, showed 
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more significant reduction of AST, ALT, ACP and total bilirubin32. 
Results recorded by Arthika et al., in 2011 shows that the ethanolic extract of Azima 
tetracantha reduced the hepatotoxin intoxication induced elevated biochemical parameters 
and decrease theprotein synthesis and accumulation of triglycerides leading to fatty liver. 
Reduction of raised bilirubin level suggests the stability of the biliary function during the 
hepatic injury with paracetamol. Treatment with ethanolic extract of Azima tetracantha 
significantly reversed it, indicating that the phytoconstituents present in this extraction have 
hepatoprotective potential29. 
A study done by Maruthy T Ekbote et el., in 2010 provides scientific evidence on 
the correlative effects of hepatoprotective activities of Azima tetracantha Lam. They induced 
hepatotoxicity by altering liver microsomal membranes in experimental animals by CCl4 
administration. The chloroform and ethanol extracts of Azima tetracantha Lam. reduced the 
hepatotoxin intoxication induced elevated biochemical parameters and decrease the protein 
synthesis30. 
Balakrishnan  et al., in 2012 reported that in the liver sections of the rats treated with 
ethanol extract of Azima tetracantha Lam. root bark extract for 7 days, the normal cellular 
architecture was retained there by further confirming the potent hepatoprotective effect of 
ethanolic extract of Azima tetracantha Lam. root bark. The ethanol (50%) extract of Azima 
tetracantha Lam. (EEAT) root bark afforded significant protection against CCl4 induced 
hepatocellular injury31. 
Hypoglycemic and antihyperlipidemic activity of Azima tetracantha Lam. 
The ethanolic leaf extract of Azima tetracantha Lam. was investigated by Nargis et 
al., in 2009 for hypoglycemic and hypolipidemic activity in alloxan-induced diabetic albino 
rats. The ethanolic leaf extract of Azima tetracantha Lam. produced significant reduction in 
plasma glucose and also had beneficial effects on the lipid profile in alloxan-induced diabetic 
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rats at the end of the treatment period32. 
ACUTE TOXICITY STUDIES: 
 Muthusamyet al.,2009 showed that the extract of Azima tetracantha Lam. possess 
antiulcer activity with LD50 of 2000 mg/kg28. 
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3.3 UROLITHIASIS 
Urolithiasis (from Greek ouron, “urine” and lithos, “stone”) is the condition where 
urinary stones are formed or located anywhere in the urinary system. The term nephrolithiasis 
(or “renal calculus”) refers to stones that are in the kidney, while ureterolithiasis refers to 
stones that are in the ureter. The term cystolithiasis (or vesical calculi) refers to stones which 
form or have passed into the urinary bladder33. 
  Urinary stones are typically classified by their location or by their chemical 
composition. In humans, calcium oxalate is a major constituent of most urinary stones. About 
80% of those with kidney stones are men. Men most commonly experience their first episode 
between 20-30 years of age, while for women the age at first presentation is somewhat later. 
Nomenclature of Stones: 
 The word “crystal ”is derived from the Greek work krystallosus, which means “ ice ” 
and is used to refer to the solid phase of substances having a specific internal structure and 
enclosed by symmetrically arranged planar surfaces. 
 The Latin word calculus means “pebble”. The crystalline constituents of urinary 
calculi in the human are varied. Some of these occur geologically, whereas others are found 
only in the animal kingdom34. 
Stones can form when urine contains too much of certain substances. These 
substances can create small crystals that become stones. The stones take weeks or months to 
form. There are different types of kidney stones. The exact cause depends on the type of 
stone35. 
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Nephrolithiasis and ureterolithiasis 
  A kidney stone, also known as a renal calculuoos is a solid concretion or 
crystal aggregation formed in the kidneys from dietary minerals in the urine. Kidney stones 
typically leave the body by passage in the urine stream, and many stones are formed and 
passed without causing symptoms. If stones grow to sufficient size (usually at least 
3millimeters (0.12n)) they can cause obstruction of the ureter. Ureteral obstruction causes 
postrenal azotemia and hydronephrosis (distension and dilation of the renal pelvis and 
calyces), as well as spasm of the ureter. This leads to pain, most commonly felt in the flank 
(the area between the ribs and hip), lower abdomen and groin (a condition called renal colic). 
Renal colic can be associated with nausea, vomiting, fever, blood in the urine, pus in the 
urine and painful urination. Renal colic typically comes in waves lasting 20 to 60 minutes, 
beginning in the flank or lower back and often radiating to the groin or genitals. 
Etiology and Precipitating Factors: 
 Urinary tract infection (UTI) which increases the alkalinity of the urine and causes 
calcium and other substance to precipitate and form renal calculi. 
 Immobility, dehydration and urinary obstruction or stasis, increasing likelihood that 
calculus forming substances well precipitate. 
 Metabolic or dietary changes, such as hyperthyroidism, hyperparathyroidism, bone 
disease, corticosteroid use, excessive vitamin A and D intake, diet high in calcium or 
purine, or other factors increasing calcium, phosphorus, uric acid and other calculus-
forming substances in the blood or urine. 
 More common in male aged 30-50 years37. 
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Types of kidney stones: 
 
 
 
 
 
Cystine Stone Calcium Stone 
Sturvite Stone Uric Acid Stone 
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 TYPES OF KIDNEY STONES 
  Urinary stones are typically classified by their location in the kidney 
(nephrolithiasis), or bladder (cystolithiasis), or ureter (ureterolithiasis), or chemical 
composition (calcium-containing, struvite, uric acid or other compounds). 
   Table 3.1 Types of Kidney stones 
Kidney 
Stone type Population Circumstances Details 
Calcium 
 Oxalate 
80% when urine is 
alkaline (ph>5.5) 
Some of the oxalate in urine is produced by the body. 
Calcium and oxalate in the diet play a part but are not the 
only factors that affect the formation of calcium oxalate 
stones. Dietary oxalate is an organic molecule found in 
many vegetables, fruits, and nuts. Calcium from bone 
may also play a role in kidney stone formation. 
Calcium 
phosphate     __ 
when urine is 
alkaline (high 
pH) 
 
Uric acid 5-10% 
when urine is 
persistently 
acidic 
Diets rich in animal proteins and purines: substances 
found naturally in all food but especially in organ meats, 
fish, and shellfish. 
Struvite 10-15% infections in the kidney 
Preventing struvite stones depends on staying infection-
free. Diet has not been shown to affect struvite stone 
formation. 
Cystine     __ rare genetic disorder 
Cystine, an amino acid (one of the building blocks of 
protein), leaks through the kidneys and into the urine to 
form crystals. 
 
 Calcium stones are most common. They are most common in men between the ages 
of 20 and 30. Calcium can combine with other substances, such as oxalate (the most common 
substance), phosphate or carbonate to form the stone. Oxalate is present in certain foods such 
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as spinach. It is also found in vitamin C supplements. Diseases of the small intestine increase 
risk of bone disease. 
 Cystine stones can form in people who have cystinuria. This disorder runs in families 
and affects both men and women. 
 Struvite stones are mostly found in women who have a urinary tract infection. These 
stones can grow very large and can block the kidney, ureter or bladder. 
 Uric acid stones are more common in men than in women. They can occur with gout 
or chemotherapy37. 
Urine calcium >300mg/24h (men), 250mg/24h (women), or 4mg/kg per 24h either sex. 
Hyperthyroidism, Cushing’s syndrome, sarcoidosis, malignant tumour, immobilization, 
vitamin D intoxication, rapidly progressive bone disease and Paget’s disease all cause 
hypercalciuria and must be excluded in diagnosis of idiopathic hypercalciuria. 
         Table 3.2 Symptoms of urolithiasis based on stone location 
                    Stone location                 Common symptoms 
Kidney Vague flank pain, hematuria 
Proximal ureter Renal colic, flank pain, upper abdominal 
pain 
Middle section of ureter Renal colic, anterior abdominal pain, flank 
pain 
Distal ureter Renal colic, dysuria, urinary frequency, 
anterior abdominal pain, flank pain 
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Fig 3.1 Mechanism of Urolithiasis38 
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MANIFESTATIONS OF STONE36 
As stones grow on the surfaces of the renal papillae or within the collecting system, they do 
not necessarily produce symptoms. Asymptomatic stones may be discovered during the 
course of radiographic studies undertaken for unrelated reasons. Stones are a common cause 
of isolated hematuria. Stones become symptomatic when they enter the ureter or occlude the 
ureteropelvic junction, causing pain and obstruction. 
Stone passage 
  A stone can traverse the ureter without symptoms, but passage usually 
produces pain and bleeding. The pain begins gradually, usually in the flank, but increases 
over the next 20-60min to become so severe that narcotics may be needed for its control. The 
pain may remain in the flank or spread downward and anteriorly toward the ipsilateral loin, 
testis or vulva. A stone in the portion of the ureter within the bladder wall causes frequency, 
urgency and dysuria that may be confused with urinary tract infection. The vast majority of 
ureteral stones <0.5cm in diameter pass spontaneously. 
 There may not be any symptoms until the stones move down the ureters through 
which urine empties into the bladder. When this happens, the stones can block the flow of 
urine out of the kidneys36. 
The main symptom is severe pain that starts suddenly and may go away suddenly: 
• Pain may be felt in the belly area or side of the back. 
• Pain may move to groin area (groin pain) or testicle (testicle pain). 
Other symptoms can include: 
• Abnormal urine color 
• Hematuria (Blood in urine) 
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• Pyuria (Pus in urine) 
• Dysuria (Burning on urination when passing stones) 
• Oliguria (Reduced urinary volume) 
• Chills 
• Fever 
• Nausea, vomiting39 
Potential Complications 
 Bleeding (may be acute or delayed for 1 to 2 weeks). 
 Sepsis 
 Renal pelvis perforation and loss of irrigating fluid into retroperitoneal area 
 Non removable calculi 
 Loss of calculus fragments into retro peritoneum40. 
CAUSES 
Dietary factors that increase the risk of stone formation include 
• Low fluid intake 
• High dietary intake of animal protein 
• Sodium 
• High fructose corn syrup 
• Oxalate 
• Grapefruit juice 
• Apple juice 
• Cola drinks 
 The biggest risk factor for kidney stone is not drinking enough fluids. Kidney stones 
are more likely to occur if less than 1 liter of urine is passed in a day33. 
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Medications Increasing the Tendency for Stone Formation 
 Acetazolamide (calcium phosphate stones) 
 Allopurinol (xanthine or oxypurinol stones) 
 Calcium carbonate 
 Chemotherapy (increased urate load) 
 Ephedra/guaifenesin 
 Indinavir/acyclovir 
 Sulfonamides 
 Triamterene 
 Vitamine C (oxalate) 
 Vitamine D, nonthiazide diuretic, steroids (hypercalciuria)41 
Diagnostic studies 
Urine analysis: Commonly shows red blood cells, white blood cells, crystals, minerals and 
pH changes. 
Urine culture: Commonly shows presence of bacteria. 
24 hours urine study: Commonly shows high levels of calcium, phosphorus, uric acid, 
creatinine, oxalate or cystine. 
Renal calculus analysis: Shows mineral composition of stones. 
Blood Studies: May show high serum level of calcium, protein, electrolyte, uric acid, 
phosphates, blood urea nitrogen, creatinine or WBCs40. 
TESTS 
• Noncontrast helical CT has become the standard for evaluation of acute urolithiasis. 
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• Renal/Bladder ultrasound; most useful screening test. 
• Abdominal plain radiography may show calcifications; uric acid calculi are 
radiolucent. 
• Intravenous excretory urography allows imaging of renal parenchyma, collecting 
system and ureters. 
• Stone component identification41. 
TREATMENT 
Treatment depends on the type of stone and the severity of the symptoms. 
Common treatments are, 
 Kidney stones that are small usually pass on their own. When the stone passes, the 
urine should be strained so the stone can be saved and tested. 
 Drinking at least 6-8 glasses of water per day to produce a large amount of urine is 
recommended. 
 Pain can be severe enough to need narcotic pain relievers. 
Calcium Stones36 
Idiopathic Hypercalciuria 
This condition is the most common metabolic abnormality found in patients with 
nephrolithiasis. It is familial and is probably a polygenic trait, although there are some rare 
monogenic causes of hypercalciuria and kidney stones such as Dent's disease, which is an X-
linked disorder characterized by hypercalciuria, nephrocalcinosis, and progressive kidney 
failure. Idiopathic hypercalciuria is diagnosed by the presence of hypercalciuria without 
hypercalcemia and the absence of other systemic disorders known to affect mineral 
metabolism. Vitamin D overactivity through either high calcitriol levels or excess vitamin D 
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receptor is a likely explanation for the hypercalciuria in many patients. Recent studies have 
shown that a polymorphism (Arg990Gly) of the calcium-sensing receptor, which leads to 
activation of the receptor, is more common in hypercalciuric subjects and probably 
contributes to higher urine calcium excretion. Hypercalciuria contributes to stone formation 
by raising urine saturation with respect to calcium oxalate and calcium phosphate. 
Treatment: Hypercalciuria 
For many years the standard therapy for hypercalciuria was dietary calcium restriction. 
However, studies have shown that low-calcium diets increase the risk of incident stone 
formation, perhaps by reducing the amount of calcium in the intestine to bind oxalate, thereby 
increasing urine oxalate levels. A 5-year prospective trial compared the efficacy of a low-
calcium diet to a low-protein, low-sodium and normal-calcium diet in preventing stone 
recurrence in male calcium stone formers. The group on the low-calcium diet had a 
significantly greater rate of stone relapse. In addition, hypercalciuric stone formers have 
reduced bone mineral density and an increased risk of fracture compared with the non-stone-
forming population. Low calcium intake probably contributes to the low bone mineral 
density. In sum, low-calcium diets are of unknown efficacy in preventing stone formation and 
carry a long-term risk of bone disease, making low-sodium and low-protein diets a superior 
treatment option.  
If diet therapy is not sufficient to prevent stones, thiazide diuretics may be used. Thiazide 
diuretics lower urine calcium and are effective in preventing the formation of stones. Three 
year randomized trials have shown a 50% decrease in stone formation in the thiazide-treated 
groups compared with the placebo-treated controls. The drug effect requires slight 
contraction of the extracellular fluid volume and high dietary NaCl intake reduces its 
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therapeutic effect. Thiazide-induced hypokalemia should be treated aggressively since 
hypokalemia will reduce urine citrate, an important inhibitor of calcium crystallization. 
Hyperuricosuria 
About 20% of calcium oxalate stone formers are hyperuricosuric, primarily because 
of an excessive intake of purine from meat and fish. The mechanism of stone formation 
probably involves salting out calcium oxalate by urate. A low-purine diet is desirable but 
difficult for many patients to achieve. The alternative is allopurinol, which has been shown to 
be effective in a randomized, controlled trial. 
Hyperoxaluria 
Oxalate is a metabolic end product in humans. Urine oxalate comes from diet and 
endogenous metabolic production, with ~40–50% originating from dietary sources. The 
upper limit of normal for oxalate excretion is generally considered to be 40–50mg per day. 
Mild hyperoxaluria (50–80mg/d) usually is caused by excessive intake of high-oxalate foods 
such as spinach, nuts and chocolate. In addition, low-calcium diets may promote 
hyperoxaluria as there is less calcium available to bind oxalate in the intestine. Enteric 
hyperoxaluria is a consequence of small-bowel disease, resulting in fat malabsorption. 
Oxalate excretion is often >100mg per day. Enteric hyperoxaluria may be caused by 
jejunoileal by pass for obesity, pancreatic insufficiency, or extensive small-intestine 
involvement from Crohn's disease. With fat malabsorption, calcium in the bowel lumen is 
bound by fatty acids instead of oxalate, which is left free for absorption in the colon. Delivery 
of unabsorbed fatty acids and bile salts to the colon injures the colonic mucosa and enhances 
oxalate absorption. Recent studies have shown that modern bariatric surgery for obesity that 
involves by passing intestinal segments, such as Roux-en-Y gastric bypass and 
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biliopancreatic diversions, may lead to hyperoxaluria that can cause kidney failure as well as 
kidney stones. The mechanism of hyperoxaluria has not been well studied. 
Primary hyperoxaluria is a rare autosomal recessive disease that causes severe 
hyperoxaluria. Patients usually present with recurrent calcium oxalate stones during 
childhood. Primary hyperoxaluria type 1 is due to a deficiency in the peroxisomal enzyme 
alanine: glyoxylate aminotransferase. Type 2 is due to a deficiency of D-glyceric 
dehydrogenase. Severe hyperoxaluria from any cause can lead to stone formation and 
produce tubulointerstitial nephropathy. 
Treatment: Hyperoxaluria 
Patients with mild to moderate hyperoxaluria should be treated with a diet low in 
oxalate and with a normal intake of calcium and magnesium to reduce oxalate absorption. 
Enteric hyperoxaluria can be treated with a low-fat, low-oxalate diet and calcium 
supplements, given with meals, to bind oxalate in the gut lumen. The oxalate-binding resin 
cholestyramine provides an additional form of therapy. Treatment for primary hyperoxaluria 
includes a high fluid intake, neutral phosphate, potassium citrate and pyridoxine (25–
200mg/d). Even with aggressive therapy, irreversible renal failure may occur. Liver 
transplantation to correct the enzyme defect, combined with kidney transplantation, has been 
successfully utilized in patients with primary hyperoxaluria. 
Hypocitraturia 
Urine citrate prevents calcium stone formation by creating a soluble complex with 
calcium, effectively reducing free urine calcium. Hypocitraturia is found in 20–40% of stone 
formers either as a single disorder or in combination with other metabolic abnormalities. It 
can be secondary to systemic disorders such as RTA, chronic diarrhoeal illness and 
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hypokalemia or it may be a primary disorder, in which case it is called idiopathic 
hypocitraturia. 
Treatment: Hypocitraturia 
Treatment is with alkali, which increases urine citrate excretion; generally, 
bicarbonate or citrate salts are used. Potassium salts are preferred as sodium loading increases 
urinary excretion of calcium, reducing the effectiveness of treatment. Two randomized, 
placebo-controlled trials have demonstrated the effectiveness of citrate supplements in 
calcium oxalate stone formers. Lemonade and other citrate-rich beverages have been used to 
treat hypocitraturia, although the increase in urine citrate is not as great as is seen with 
pharmacologic dosing of citrate salts. 
Idiopathic Calcium Lithiasis 
Some patients have no metabolic cause for stones despite a thorough metabolic 
evaluation. The best treatment appears to be high fluid intake so that the urine specific gravity 
remains at 1.005 throughout the day and night. Thiazide diuretics and citrate therapy may 
help to reduce crystallization of calcium salts, but there have been no prospective trials in this 
patient population. Oral phosphate at a dose of 2g phosphorus daily may lower urine calcium 
and increase urine pyrophosphate, thereby reducing the rate of recurrence. Orthophosphate 
causes mild nausea and diarrhea, but tolerance may improve with continued intake. 
Uric Acid Stones36 
Persistently acidic urine is the major risk factor for uric acid stone formation. When 
urine pH is low, the protonated form of uric acid predominates and is soluble in urine at 
concentrations of 100mg/L. Concentrations above this level represent supersaturation that 
causes crystals and stones to form. Common causes of acidic urine and uric acid stones 
include metabolic syndrome, chronic diarrhoeal states, gout and idiopathic uric acid lithiasis. 
Review of Literature 
 
Institute of Pharmacology, MMC Page 30 
 
As the prevalence of obesity increases, metabolic syndrome is becoming an increasingly 
important cause of uric acid stone formation, as insulin resistance leads to a decrease in 
ammoniagenesis, requiring that the metabolic acid load be excreted as titratable acid. 
Hyperuricosuria, when present, increases super saturation, but urine of low pH can be 
supersaturated with uric acid even though the daily excretion rate is normal. 
Myeloproliferative syndromes, chemotherapy for malignant tumors and Lesch-Nyhan 
syndrome cause such massive production of uric acid and consequent hyperuricosuria that 
stones and uric acid sludge form even at a normal urine pH. Obstruction of the renal tubules 
by uric acid crystals can cause acute renal failure. 
Treatment: Uric Acid Lithiasis 
The two goals of treatment are to raise urine pH and lower excessive urine uric acid 
excretion to <1g/d. Supplemental alkali, 1–3 mEq/kg of body weight per day, should be given 
in three or four divided doses, one of which should be given at bedtime. The goal of 
treatment should be a urine pH between 6 and 6.5 in a 24-h urine collection. Increasing urine 
pH above 6.5 will not provide additional benefit in preventing uric acid crystallization but 
increases the risk of calcium phosphate stone formation. The form of the alkali may be 
important. Potassium citrate may reduce the risk of calcium salts crystallizing when urine pH 
is increased, whereas sodium alkali salts may increase the risk. A low-purine diet should be 
instituted in uric acid stone formers with hyperuricosuria. Patients who continue to form uric 
acid stones despite treatment with fluids, alkali and low-purine diet. 
Cystinuria and Cystine Stones 
In this inherited disorder, proximal tubular and jejunal transport of the dibasic amino 
acids cystine, lysine, arginine, and ornithine is defective, and excessive amounts are lost in 
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the urine. Clinical disease is due solely to the insolubility of cystine. Cystine crystals plug 
terminal collecting ducts, and stones may grow as an extension of those plugs. Damage to the 
papillae and medulla from crystal obstruction is the probable reason why kidney function is 
reduced in cystinuria compared with routine stone disease. 
Pathogenesis 
Cystinuria occurs because of defective transport of dibasic amino acids by the brush 
borders of renal tubule and intestinal epithelial cells. Disease-causing mutations have been 
identified in both the heavy and light chains of a heteromeric amino acid transporter found in 
the proximal tubule of the kidney. Cystinuria is classified into two main types, based on the 
urinary excretion of cystine in obligate heterozygotes. In type I cystinuria, heterozygotes have 
normal urine cystine excretion; thus, type I has an autosomal recessive pattern of inheritance. 
A gene on chromosome 2 that has been designated SLC3A1 encodes the heavy chain of the 
transporter and has been found to be abnormal in type I. In non-type I cystinuria, 
heterozygotes have moderately elevated urine cystine excretion, with homozygotes having a 
much higher urine cystine excretion. Non-type I is inherited as a dominant trait with 
incomplete penetrance. Non-type I is due to mutations in the SLC7A9 gene on chromosome 
19, which encodes the light chain of the heteromeric transporter. In rare cases, mutations of 
the SLC7A9 gene can lead to a type I phenotype. 
Diagnosis 
Cystine stones are formed only by patients with cystinuria, but 10% of stones in 
cystinuric patients do not contain cystine; therefore, every stone former should be screened 
for the disease. The sediment from a first morning urine specimen in many patients with 
homozygous cystinuria reveals typical hexagonal, platelike cystine crystals. Cystinuria can 
also be detected by using the urine sodium nitroprusside test. Because the test is sensitive, it 
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is positive for cystinuria in many asymptomatic heterozygotes. A positive nitroprusside test 
or the finding of cystine crystals in the urine sediment should be evaluated by measurement 
of daily cystine excretion. Cystine stones seldom form in adults unless urine excretion is at 
least 300mg/d. 
Treatment: Cystinuria and Cystine Stones 
High fluid intake, even at night, is the cornerstone of therapy. Daily urine volume 
should exceed 3L. Raising urine pH with alkali is helpful provided that the urine pH exceeds 
7.5. A low-salt diet (100mmol/d) can reduce cystine excretion up to 40%. Because side 
effects are common, drugs such as penicillamine and tiopronin, which form mixed soluble 
disulfide cysteine-drug complexes, should be used only when fluid loading, salt reduction and 
alkali therapy are ineffective. Low-methionine diets have not proved to be practical for 
clinical use, but patients should avoid protein gluttony. 
Struvite Stones 
These stones are a result of urinary infection with bacteria, usually Proteus species, 
which possess urease, an enzyme that degrades urea to NH3 and CO2. The NH3 hydrolyzes to 
NH4+ and raises urine pH to 8 or 9. The NH4+ precipitates PO43– and Mg2+ to form 
MgNH4PO4 (struvite). Struvite does not form in urine in the absence of infection, because 
NH4+ concentration is low in urine that is alkaline in response to physiologic stimuli. Chronic 
Proteus infection can occur because of impaired urinary drainage, urologic instrumentation or 
surgery and especially with chronic antibiotic treatment, which can favor the dominance of 
Proteus in the urinary tract. The presence of struvite crystals in urine, rectangular prisms that 
resemble coffin lids, indicates infection with urease-producing organisms. 
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Treatment: Struvite Stones 
Complete removal of the stone with subsequent sterilization of the urinary tract is the 
treatment of choice for patients who can tolerate the procedures. Percutaneous 
nephrolithotomy is the preferred surgical approach for most patients. At times, extracorporeal 
lithotripsy may be used in combination with a percutaneous approach. Open surgery is rarely 
required. Irrigation of the renal pelvis and calyces with hemiacidrin, a solution that dissolves 
struvite, can reduce recurrence after surgery. Stone-free rates of 50–90% have been reported 
after surgical intervention. Antimicrobial treatment is best reserved for dealing with acute 
infection and for maintenance of sterile urine after surgery. Urine cultures and culture of 
stone fragments removed at surgery should guide the choice of antibiotic. For patients who 
are not candidates for surgical removal of a stone, acetohydroxamic acid, an inhibitor of 
urease, can be used. Unfortunately, acetohydroxamic acid has many side effects, such as 
headache, tremor and thrombophlebitis that limit its use. 
Surgical options available are: 
 Extracorporeal shock-wave lithotripsy is used to remove stones slightly smaller than a 
half an inch that are located near the kidney or ureter. It uses sound or shock waves to 
break up stones. Then, the stones leave the body in the urine. 
 Percutaneous nephrolithotomy is used for large stones in or near the kidney, or when 
the kidneys or surrounding areas are incorrectly formed. The stone is removed with 
tube (endoscope) that is inserted into the kidney through a small surgical cut. 
 Ureteroscopy may be used for stones in the lower urinary tract. 
 Rarely, open surgery (nephrolithotomy) may be needed if other methods do not work 
or are not possible37. 
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Herbal Home Remedies for Kidney Stones: 
 Kidney beans 
 Watermelon 
 Apple 
 Basil 
 Pomegranate 
 Celery 
 Vitamin B 
 Horsetail tea 
 Lemon juice, olive oil, raw apple cider vinegar 
 Coconut water and barley water44 
Herbal medicines act by multiple mechanisms like 
 Helping in spontaneous passage of calculi by increasing urine volume, pH and 
anticalcifying activity (Diuretic activity). 
 Balancing the Inhibitor and promoter of the crystallization in urine and affecting the 
crystal nucleation, aggregation and growth (Crystallization inhibition activity). 
 Relieving the binding mucin of calculi (Lithotroptic activity). 
 Improving renal function. 
 Regulation of oxalate metabolism. 
 Regulating the crystalloid-colloid imbalance and improving renal function, thus 
preventing recurrence of urinary calculi. 
 Improving renal tissue antioxidant status and cell membrane integrity and preventing 
recurrence (Antioxidant activity). 
 Exerting significant anti-infective action against the major causative organisms 
(Antimicrobial activity). 
 ACE and Phospholipase A2inhibition. 
 Relieving symptoms like pain, burning micturition and haematuria45 (Analgesic and 
anti-inflammatory activity). 
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Medicinal Herbs in the Treatment of Urolithiasis: 
• Ammi visnaga 
• Pergularia daemia 
• Momordica charantia 
• Achyranthus aspera 
• Moringa oliefera 
• Quercus salicina 
• Phyllanthus niruri 
• Raphanus sativus44 
Available Herbal Formulations for Urolithiasis: 
 Cystone 
 Calcury 
 Chandraprabha bati 
 Trinapanchamool 
 Rencare Capsule 
 Patherina tablet 
 Ber Patthar Bhasma 
 Chander Prabha vati 
It was felt that herbal medication to treat urolithiasis is the need of the hour. A 
standardised polyherbal formulation in a convenient dosage form along with scientific 
study would contribute significantly in the treatment of urolithiasis. In the present study, 
plant such as Azima tetracantha Lam. was selected for evaluate its antiurolithiatic 
activity. 
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PLANT COLLECTION AND IDENTIFICATION 
 Dried whole plant of Azima tetracantha. Lam was collected from the forest around 
Panakkudi, Trinelveli District, Tamilnadu (INDIA), in the month of July 2013. It was 
authenticated by Prof. V. Chelladurai, Research Officer-Botany (Scientist-C) (RTD), Central 
Council for Research in Ayurveda and Siddha, Govt. of India. 
PREPARATION OF PLANT EXTRACT: 
 The powdered plant material (50g) was extracted by Hot continuous soxhlet 
extraction method. The plant material was extracted with Ethanol (99.9% v/v) (500ml), Ethyl 
acetate (500ml), Chloroform (500ml) and Petroleum ether (500ml) for four days in a soxhlet 
apparatus28. 
 It is a process of continuous extraction method in which the solvent can be circulated 
through the extractor for several times. The vapour from the solvent are taken to the 
condenser and the condensed liquid is returned to the extract for continuous extraction .The 
apparatus consist of body of extractor (thimble) attached with side siphon tube, lower end 
attached with distillation flask and the mouth of the extractor is fixed to the condenser by the 
standard joints. 
Procedure: 
 Weighed about 50g dried powdered plant and transferred into a thimble for 
packing. 
 While packing, the content was wetted with Ethanol, Ethyl acetate, 
Chloroform and Petrolium ether respectively and poured until the siphon tube 
was filled. 
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 A piece of porcelain was added into the round bottom flask to avoid bumping 
effect. 
 After assembling the extractor, the plant material was extracted at about (40-
45°C), (35-40°C), (40-45°C), (20-30°C), temperature respectively until the 
colour of the solution in the siphon tube became pale. 
 The extracts obtained were dried at room temperature and the yield was stored 
in air tight container. 
 The Theoretical yield obtained was 
Ethanol extract yield           : 7.5 %w/w 
Ethyl acetate extract yield     : 5.2 %w/w 
Chloroform extract yield       : 6.3 %w/w 
Petrolium ether extract yield: 2.8 %w/w 
DRUGS AND CHEMICALS 
 Ethanol, Ethyl acetate, Chloroform, Petrolium ether, Cystone, Ethylene glycol. 
4.1PHYTOCHEMICAL ANALYSIS28 
1. TEST FOR ALKALOIDS: 
 A small portion of the extract was stirred with few drops of dilute hydrochloric acid 
and filtered. The filtrate was tested carefully with various alkaloidal reagents such as Mayer’s 
reagent (cream precipitate), Dragendroff’s reagent (orange brown precipitate), Hager’s 
reagent (yellow precipitate), and Wagner’s reagent (reddish brown precipitate). 
2. TEST FOR FLAVONOIDS: 
Schinado’s test: To the extract, a few magnesium turnings and few drops of concentrated 
hydrochloric acid were added, boiled for 5minutes and red colour indicates the presence of 
flavonoids. 
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 Sodium hydroxide test: To the extract in ethanol, 10% sodium hydroxide was added. 
Dark yellow colouration indicates the presence of flavonoids. 
3. TEST FOR TANNINS AND PHENOLIC COMPOUNDS 
 The extract was dissolved in distilled water. The extract was then divided into three 
parts. A sodium chloride solution 10% was added to one portion of test’s extract, 1% gelatin 
solution to second portion and the gelatin salt reagent to third portion. Precipitation with the 
later reagent or with both the gelatin salt reagent was indicative of the presence of tannins. 
Precipitation of sodium chloride solution indicated a false-positive test. Positive tests were 
confirmed by the addition of a few drops of dilute ferric chloride (1% Ferric chloride) to test 
extracts, which gave black or green coloration. 
 The extract was mixed with lead acetate solution and observed for white precipitate. 
4. TEST FOR TERPENOIDS 
Noller’s test: The extract was warmed with tin and thionyl chloride. Pink coloration 
indicates the presence of terpenoids 
5. TEST FOR GLYCOSIDES 
 Borntrager’s test: A small amount of extract was hydrolysed with hydrochloric acid 
for few hours on a waterbath and the hydrolysate was extracted with benzene. The benzene 
layer was treated with dilute solution and was treated with dilute solution and was observed 
for formation of reddish pink color. 
 Legal’s test: The extract was dissolved in pyridine and was made alkaline with few 
drops of 10% sodium hydroxide and then freshly prepared sodium nitroprusside was added 
and observed for the formation of blue color. 
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6. TEST FOR SAPONINS 
Foam test: A small amount of extract was extracted with petroleum ether. To the 
insoluble residue left after extraction, a few ml of water was added and shaken vigorously for 
15 minutes and was observed for the formation of honeycomb froth that persisted for at least 
30 minutes. 
7. TEST  FOR PROTEIN: 
Biuret test: The extract is treated with an equal volume of 1% strong sodium 
hydroxide followed by a few drops of copper (II) sulphate, formation of purple colour 
indicates the presence of protein. 
Million’s test: To the extract million’s reagent is added, a white precipitate is 
produced, while heating it turns brick red colour, indicates the presence of protein. 
8. TEST FOR MUCILAGE:  
The extract is treated with aqueous potassium hydroxide, swelling indicates the 
presence of mucilage. 
9. TEST FOR CARBOHYDRATES: 
Molish’s test: To the extract few drops of α-naphthol solution in alcohol, con.H2SO4 
is added at the side of test tube, formation of violet ring at the junction of two liquids 
indicates the presence of carbohydrates. 
10. TEST FOR PHYTOSTEROLS: 
• Libermann – Burchard test: 1 mg of the extract was dissolved in few drops of 
chloroform, 3 ml of acetic anhydride and 3 ml of glacial acetic acid. Warmed, 
cooled under tap water and drops of concentrated sulphuric acid was added 
along the side of the test tube, formation of bluish green colour indicates the 
presence of steroids. 
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I) IN VITRO CALCIUM OXALATE CRYSTALLIZATION INHIBITION:42,43 
Sample preparation:   The various extraction of plant material was ready to use. 
Experiment: 
           The precipitation of calcium oxalate at 37oC and pH 6.5 has been studied by the 
measurement of turbidity at 620nm. A spectrophotometer UV/Vis (SHIMADZU 1800) was 
employed to measure the developed turbidity due to the formation of calcium oxalate. 
Chemicals used: 
Chemicals used were of pure and analytical grade. 
1. Calcium chloride dehydrate (CaCl2.2H2O) 
2. Sodium oxalate (Na2C2O4) 
3. Sodium chloride (NaCl) 
Procedure: 
Study without inhibitor: 
           The solutions of CaCl2.2H2O (10mM) and Na2C2O4 (4mM) were prepared using 
sodium chloride solution (0.15M). A volume of 1.5ml of calcium chloride dehydrate was 
transferred in to the cell and blank reading was taken. 1.5ml of sodium oxalate solution was 
added to the previous volume, and the turbidity measurement was immediately started for a 
period of 10min. For each experiment, six replicates were taken. 
Study with inhibitor: 
           The inhibitor (100%) was prepared by taking 0.5g of the extract with 60ml of sodium 
chloride (0.15mM). From this inhibitor, prepare diluted inhibitory solutions (10%, 50%) 
Materials and Methods 
 
Institute of Pharmacology, MMC Page 42 
 
using solvent such as sodium chloride solution (0.15mM). A mixture of 1ml of calcium 
chloride dehydrate (10mm) and 1ml of inhibiting solution was versed in the cell. Take a 
blank reading, and then a volume of 1ml of sodium oxalate (4mM) was added and the 
measurement was immediately started for a period of 10minutes. 
           The % of inhibition was calculated using the following formula: 
                                          I (%) = [1-Ti/ Tc] x 100 
Where, 
Ti is turbidimetric slope with inhibitor, 
Tc is turbidimetric slope without inhibitor. 
Microscopic study: 
           The photographs were taken using a microscope optic equipped with a digital camera 
and connected with a microcomputer. At a time corresponding to the stage of growth and 
aggregation, a drop of the mixture of crystallizable solution, or inhibitory solution was placed 
in the glass slide, which was immediately placed under the objective of the microscope. 
II) IN-VIVO ANTIUROLITHIASIS ACTIVITY OF VARIOUS EXTRACT OF Azima 
tetracantha Lam. ON ETHYLENE GLYCOL INDUCED UROLITHIASIS IN 
RATS(46,47,48,49) 
Experimental Animals: 
The present study was conducted after obtaining approval from the Institutional Animal 
Ethics Committee and this protocol met the requirements of national guidelines of CPCSEA 
(PROPOSAL NO: Vide. 14/243/CPCSEA). The Wistar albino rats (150-200g) used for this 
study were procured from Animal house, Madras Medical College, Chennai, India. 
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Quarantine and Acclimatization: 
Quarantine is the separation of newly received animals from those already in the 
facility until the health and possibly the microbial status of the newly received animals have 
been determined. The newly procure Wistar albino rats were quarantined for the period of 
one week to minimize the chance of introduction of pathogens into established animals and 
allowed to develop the psychological, physiological and nutritional stabilization before their 
use.  
Housing: 
The animals were housed in well ventilated animal house which was maintained at a 
constant temperature and relative humidity of 55 to 60%. The animals were housed in 
spacious polypropylene cages and paddy husk was utilized as bedding material. 
Diet and water: 
The animals were maintained on standard pellet diet and purified water. The animals 
were provided with food and water ad libitum except during fasting. The bed material was 
changed twice a week. 
Animal identification: 
All animal cages used in the study had a proper identification i.e., labels. Each animal 
in the cage was marked either on head or body or tail with picric acid for their appropriate 
identification. 
IN-VIVO ANTIUROLITHIASIS EVALUATION 
 The antiurolithiasis activity of Azima tetracantha Lam. was evaluated in urolithiatic 
wistar rats. Urolithiasis was induced by oral administration of ethylene glycol (0.75% v/v) in 
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drinking water. The antiurolithiatic effect of the plant extract was compared with standard 
drug Cystone. 
Ethylene Glycol Induced Urolithiasis Model(46,47,48,49) 
 After a week of acclimatization, the rats were divided into seven groups containing 
six animals in each.  
Table 4.1 In vivo anti-urolithiasis Experimental design 
Group                                          Treatment No.of animals 
I Normal control 6 
II Ethylene Glycol (0.75% v/v) for 28 days 6 
III Ethylene Glycol (0.75% v/v) for 28 days + standard drug 
Cystone 750mg/kg bw,p.o (15-28th day) 
6 
IV Ethylene Glycol (0.75% v/v) for 28 days + Ethanolic extract of 
AT 200mg/kg bw,p.o (15-28th day) 
6 
V Ethylene Glycol (0.75% v/v) for 28 days + Ethyl acetate 
extract of AT 200mg/kg, bw,p.o (15-28th day) 
6 
VI Ethylene Glycol (0.75% v/v) for 28 days + Chloroform extract 
of AT 200mg/kg bw,p.o (15-28th day) 
6 
VII Ethylene Glycol (0.75% v/v) for 28 days + Petrolium extract 
of AT 200mg/kg bw,p.o (15-28th day) 
6 
 
Assessment of Antiurolithiatic Activity 
On 28thday all animals which were kept in metabolic cages are taken and urine 
samples were collected. Animals had free access to drinking water during the urine collection 
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period. A drop of concentrated hydrochloric acid was added to the urine before being stored 
at 40C. Urine was analyzed for urine volume, pH, calcium, phosphate, oxalate and  
magnesium content using the method of Bahuguna et al.,50. 
4.3.1 URINE VOLUME 
 Animals were placed in separate metabolic cages for 24h and total urinary volume 
was measured using the cylinder and reported in ml50. 
4.3.2 URINE pH 
 Uric acid crystals were found to deposit most frequently in the concentrated acid 
urine. Thus, the acidity of the urine was tested using pH meter50. 
 
ESTIMATION OF CALCIUM IN URINE (BioChain) 
CALCIUM ASSAY KIT (Z5030014) 
 Calcium is measured to moniter diseases of the bone or calcium regulation disorders. 
Increased calcium levels in serum are reported in hyperparathyroidism, metabolic bone 
lesions and hypervitaminosis, while decreased levels are observed in hypoparathyroidism, 
nephrosis, rickets, steatorrhea, nephritis and calcium-losing syndromes.  
 Urinary calcium levels aid the clinician in understanding how the kidneys handle 
calcium in certain diseases of the parathyroid gland. Urinary calcium levels are also essential 
in the medical evaluation of kidney stones. 
Principle 
 Simple, direct and automation-ready procedures for measuring calcium concentration 
in biological samples are becoming popular in Research and Drug Discovery. Biochain’s 
calcium assay kit is designed to measure calcium directly in biological samples without any 
pretreatment. A phenosulphonephthalein dye in the kit forms a very stable blue colored 
complex specifically with free calcium. The intensity of the color, measured at 612nm is 
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directly proportional to the calcium concentration in the sample. The optimized formulation 
minimizes any interference by substances such as magnesium, lipid, protein and bilirubin. 
Kit contents (500 tests in 96-well plates) 
 Reagent A: 50ml 
 Reagent B: 50ml 
 Calcium standard: 1mL 20mg/dl Ca2+ 
Storage conditions: 
 The kit is shipped at room temperature. Store reagent and standard at 4oc. Shelf life: 
12 months after receipt. 
Procedure 
Reagent Preparation: 
 Prepare enough working reagent by combining equal volumes of reagent A and B. 
Equilibrate to room temperature before use. 
Procedure using 96-well plate: 
1. Dilution: 
Transfer 5ml diluted standards and samples into wells of a clear bottom 96-well 
plate. Store diluted standards at 4oc for future use. 
Premix H2O Ca (mg/dl) 
100ml + 0ml 100 20 
80ml + 20ml 100 16 
60ml + 40ml 100 12 
40ml + 60ml 100 8 
30ml + 70ml 100 6 
20ml + 80ml 100 4 
10ml + 90ml 100 2 
0ml + 100ml 100 0 
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2. Add 200ml working reagent and tap lightly to mix. 
3. Incubate 3min at room temperature and read optical density at 570- 650nm (peak 
absorbance at 612nm). 
Procedure using cuvette: 
1. Set up tubes for diluted standards and samples. Transfer 15ml diluted standards 
and samples to appropriately labeled tubes. 
2. Add 1000ml working reagent and vortex to mix. Incubate 3min. Transfer to cuvet 
and read optical density at 612nm. 
CALCULATION 
 Substrate blank OD from the standard OD values and plot the OD against Ca2+ 
standard concentrations. Determine the slope using linear regression fitting. Calcium 
concentration of the sample is calculated as 
   =OD sample –OD blank/Slope. 
 OD sample and OD blank are read at OD 612nm values of sample and blank (water or 
buffer in which the sample was diluted). 
Conversions: 1mg/dl Ca2+ equals 250mM, 0.001% or 10ppm. 
ESTIMATION OF MAGNESIUM IN URINE 
MAGNESIUM KIT (Calmagite method) 
 Magnesium, along with potassium, is a major intracellular cation. It is an activator of 
various enzymes. It is also involved in amino acid activation and protein synthesis. Increased 
levels are found in dehydration, addition’s disease and uremia. Decreased levels are found in 
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malabsorption, during treatment of diabetic coma, chronic renal disease, chronic alcoholism, 
pancreatitis and hyperthyroidism. 
Principle: 
 Magnesium combines with Calmagite in an alkaline medium to form a red colored 
complex. Interference of calcium and proteins are eliminated by the addition of specific 
chelating agents and detergents. Intensity of the colour formed is directly proportional to the 
amount of magnesium present in the sample. 
    alkaline 
Magnesium + Calmagite                                Red colour complex 
    Medium 
Contents:     25ml    75ml 
L1: Buffer reagent    12.5ml    37.5ml 
L2: Colour reagent    12.5ml    37.5ml 
S: Magnesium standard (2.0 mEq/L)  2ml    2ml 
Storage/ stability: 
 Contents are stable at 2-8oc till the expiry mentioned on the label. 
Reagent preparation: 
 Reagents are ready to use. Protect from bright light. 
Working reagent: For large assay series a working reagent may be prepared by mixing 
equal volume of L1 (Buffer reagent) and L2 (colour reagent). The working reagent is stable at 
2-8oc for at least one month keep tightly closed. 
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Sample material: 
        Urine: 24hr. collected urine should be acidified to a pH of 2-3 by the addition of approx. 
10-15 ml of HCl and diluted 1+3 with distilled water before use. Multiply results by 4. 
Procedure: 
Wavelength / filter : 510nm 
Temperature  : Room temperature 
Light path  : 1cm 
Pipette into clean dry test tubes labeled as Blank (B), Standard (S) and Test(T). 
Addition sequence Blank (ml)  Standard (ml) Test (ml) 
Buffer reagent (L1) 
Colour reagent (L2) 
Distilled water 
Magnesium standard (S) 
Sample 
    0.5 
    0.5 
    0.01 
     - 
     - 
0.5 
0.5 
- 
0.01 
- 
0.5 
0.05 
- 
- 
0.01 
 Mix well and incubate at room temperature (25oc) for 5min. Measure the absorbance 
of Standard (Abs.S) and Test (Abs.T) against the blank, within 30min. 
System parameters: 
Reaction  : End point   Sample volume: 0.01ml 
Wave length  : 510nm   Reagent volume: 1.00ml 
Zero setting  : Reagent Blank  Reaction slope   : Increasing 
Incubator. Temp : Room temp   Linearity   : 10mEq/ L 
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Incubation time : 5min    Units    : mEq/ L 
Standard  : 2.0mEq/L 
Calculation:     
Abs. T 
Magnesium in mEq/L =        x 2 
     Abs. S 
 Levels of calcium, magnesium in urine and urea, uric acid, creatinine in serum were 
estimated by standard kits of CREST BIOSYSTEMS, Goa, India. 
ESTIMATION OF PHOSPHORUS IN URINE 
PHOSPHORUS KIT (Molybdate U.V method) 
 Phosphorus is mainly combined with calcium and is found in the bones. 
Approximately 15% exists as inorganic phosphorus or phosphate esters. It is involved in the 
carbohydrate metabolisms and is a component of many other substances. Increased levels are 
found in hypothyroidism, renal failure, bone metastasis and liver disease. Decreased levels 
are found in hyperthyroidism, rickets and vitamin D deficiency. 
Principle: 
 Phosphate ions in an acidic medium react with ammonium molybdate to form a 
phosphomolybdate complex. This complex has an absorbance in the ultraviolet range and is 
measured at 340nm. Intensity of the complex is directly proportional to the amount of 
inorganic phosphorus present in the sample. 
Phosphorus + Ammonium Molybdate ----------- Phosphomolybdate complex 
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Contents     25ml   2 x 75ml 
L1: Acid Reagent    60ml   2 x 60ml 
L2: Molybdate Reagent   15ml   2 x 15ml 
S: Phosphorus Standard (5mg/dl) 2ml 5ml   5ml 
Storage/ stability: 
Contents are stable at room temperature (25-30oc) till the expiry mentioned on the label. 
Reagent preparation 
 Reagents are ready to use. 
Working Reagent: 
 Pour the contents of 1 bottle of L2 (Molybdate Reagent) into 1 bottle of L1 (Acid 
Reagent). This working reagent is stable for at least 6 months when stored at 2-8oC. Upon 
storage this working reagent may develop a slight blue colour however this does not affect 
the performance of the reagent. 
 Alternatively for flexibility as much of working reagent may be made as and when 
desired by mixing together 4 parts of L1 (Acid reagent) and 1 part of L2 (Molybdate reagent). 
Alternatively 0.8ml of L1 and 0.2ml of L2 may also be used instead of 1ml of the working 
reagent directly during the assay. 
Sample material: 
 Urine: Acidify the urine with a few drops of conc. HCl and dilute 1+ 19 before the 
assay (results x 20). 
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Procedure: 
Wavelength/ filter   : 340nm 
Temperature    : Room temperature 
Light path    : 1cm 
Pipette into clean dry test tubes labeled as Blank (B), Standard (S) and Test (T). 
Addition sequence       Blank (ml) Standard (ml) Test (ml) 
Working reagent 
Distilled water 
Phosphorus Standard (S) 
Sample 
      1.0 
      0.01 
      - 
      - 
1.0 
- 
0.01 
- 
1.0 
- 
- 
0.01 
 
 Mix well and incubate at room temperature for 5min. Measure the absorbance of the 
standard (Abs. S) and Test Sample (Abs. T) against the blank, within 60min. 
System parameters: 
Reaction  : UV End point  Sample volume: 0.01ml 
Wave length  : 340nm   Reagent volume: 1.00ml 
Zero setting  : Reagent Blank  Reaction slope   : Increasing 
Incubator. Temp : Room temp   Linearity   : 20mg/dl 
Incubation time : 5min    Unit    : mg/dl 
Standard  : 5mg/ dl 
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Calculation: 
      Abs. T 
Magnesium in mg/ dl  = ------------------------   x 5 
      Abs. S 
 
4.4 SERUM ANALYSIS 
 After the experimental period, blood was collected from the retro-orbital under 
anesthetic conditions. The blood was collected and serum was separated by centrifugation at 
10,000 rpm for 10min. The serum supernatant was collected and then diluted within the ratio 
of 1:10. Aliquots of the diluted serum were used for the determination of serum constituents 
like creatinine, uric acid and urea nitrogen using the method of Atef and Attar and serum 
enzyme activities51. 
4.5 COLLECTION OF KIDNEY SAMPLES 
 At the 29th day, one animal from each experimental animal groups were sacrificed, 
kidney were removed immediately and washed with ice cold saline. 10% tissue homogenate 
was prepared by homogenizing 1g of chopped kidney tissue in 10ml of 0.1M tris HCl 
homogenizing buffer at pH 7.5. The homogenate was used for assaying the enzyme 
activities(52). 
Chemicals: 
 All the chemicals used in the present study were of analytical reagent grade. 
4.6 ESTIMATION OF BIOCHEMICAL MARKERS(53,54,55) 
 The serum and tissue homogenate was used to assay the marker enzymes in serum 
and tissue constituents like ACP, ALP, AST, ALT and LDH according to the method of King  
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et al., (1965a), King and Armstrong (1934), Reitman and Frankel (1957), Reitman and 
Frankel (1957) and King (1965b) respectively. 
ESTIMATION OF UREA AND BLOOD UREA NITROGEN 
UREA KIT 
 Urea is the end product of the protein metabolism. It is synthesized in liver from the 
ammonia produced by the catabolism of ammonia acids. It is transported by the blood to the 
kidneys from where it is excreted. Increased levels are bound in renal diseases, urinary 
obstructions, shock, congestive heart failure and burns. Decreased levels are found in liver 
failure and pregnancy. 
Principle: Urea is an acidic medium condenses with Diacetyl monoxime at 100oc to form a 
red coloured complex. Intensity of the colour formed is directly proportional to the amount of 
urea present in the sample. 
 Urea + Diacetyl monoxime ------------------ Red Coloured Complex 
Contents:    25ml    75ml 
L1: Urea Reagent   75ml    150ml 
L2: Acid Reagent   75ml    150ml 
L3: DAM Reagent   75ml    150ml 
S: Urea Standard (40mg/dl)  5ml    5ml 
Storage/ stability: 
 All reagents are stable at room temperature till the expiry mentioned on the label. 
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Reagent Preparation: 
 Reagents are ready to use. Do not pipette with mouth. 
Sample material: 
Serum. Urea reported to be stable in the serum for 5 days when stored at 2-8oc. 
Procedure: 
Wavelength/ filter  : 520nm (Hg 546 nm) / Green 
Temperature   : 100oc 
Light path   : 1cm 
Addition sequence Blank (B) ml Standard (S) ml Test (T) ml 
Urea reagent (L1) 
Acid reagent (L2) 
DAM reagent 
Distilled water 
Urea Standard (S) 
Sample 
1.0 
1.0 
1.0 
0.01 
- 
- 
1.0 
1.0 
1.0 
- 
0.01 
- 
1.0 
1.0 
1.0 
- 
- 
0.01 
Pipette into clean dry test tubes labeled as Blank (B), Standard (S) and Test (T). 
Mix well and keep the test tubes in boiling water (100oc) for 10min. Cool under running tap 
water and measure the absorbance of the standard (Abs. S) and Test sample (Abs. T) against 
the blank. 
System parameters: 
Reaction  :  End point   Sample volume: 0.01ml 
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Wave length  : 520nm   Reagent volume: 3.00ml  
Zero setting  : Reagent Blank  Reaction slope   : Increasing 
Incubator. Temp : 100oc    Linearity   : 70mg/dl 
Incubation time : 10min   Unit    : mg/dl 
Standard  : 40mg/ dl  
Calculation: 
     Abs. T 
Urea in mg/ dl  = ----------------------- X 40 
     Abs. S      
Blood Urea Nitrogen  = Urea in mg/ dl x 0.467 
ESTIMATION OF URIC ACID IN SERUM 
URIC ACID KIT (Uricase / PAP method) 
 Uric acid is the end product of purine metabolism. Uric acid is excreted to a large 
degree by the kidney and to a smaller extent in the intestinal tract by microbial degradation. 
Increased levels are found in Gout, arthritis, impaired renal functions and starvation. 
Decreased levels are found in Wilson’s disease, Fanconis syndrome and yellow atrophy of 
liver. 
Principle: 
 Uricase converts uric acid to allantoin and hydrogen peroxide. The hydrogen peroxide 
formed further reacts with a phenolic compound and 4 aminoantipyrine by the catalytic 
action of peroxidase to form a red coloured quinoneimine eye complex. Intensity of the 
colour formed is directly proportional to the amount of uric acid present in the sample. 
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      Uricase 
 Uric acid + H2O      ----------------    Allantoin + H2O2 
 
  Peroxidase     
 H2O2 + 4 Aminoantipyrine    --------------   Red Quinoneimine dye + H2O 
+ Phenolic compound 
 
Contents:   25ml  75ml  2X75ml  2X150ml 
L1: Buffer reagent  20ml  60ml  2X60ml  2X120ml 
L2: Enzyme reagent  5ml  15ml  2X15ml  2X30ml 
S: Uric acid Standard  5ml  5ml  5ml   5ml 
       (8mg/ dl) 
Storage/ stability: 
 All reagents are stable at 2-8oc till the expiry mentioned on the label. 
Reagent Preparation: 
 Reagents are ready to use. 
Working reagent: 
 Pour the contents of 1 bottle of L2 (Enzyme Reagent) into 1 bottle of L1 (Buffer 
reagent). This working reagent is stable for at least 4 weeks when stored at 2-8oc. Upon 
storage this working reagent may develop a slight pink colour however this does not affect 
the performance of the reagent. 
 Alternatively for flexibility as much of working reagent may be made as and when 
desired by mixing together 4 parts of L1 (Buffer reagent) and 1 part of L2 (Enzyme reagent). 
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Alternatively 0.8ml of L1 and 0.2ml of L2 may also be used instead of 1ml of the working 
reagent directly during the assay. 
Sample material: 
        Serum. Uric acid is reported to be stable in the sample for 3-5 days when stored at 2-8oc. 
Procedure: 
Wave length/ filter  : 520nm / Yellow Green  
Temperature   : 37oc / Room temperature 
Light path   : 1cm 
Addition sequence Blank (ml) Standard (ml) Test (ml) 
Working reagent 
Distilled water 
Phosphorus Standard (S) 
Sample 
1.0 
0.02 
- 
- 
1.0 
- 
0.02 
- 
1.0 
- 
- 
0.02 
 
 Pipette into clean dry test tubes labeled as Blank (B), Standard (S) and Test (T). 
Mix well and keep the test tubes in boiling water (100oc) for 10min. Cool under running tap 
water and measure the absorbance of the standard (Abs. S) and Test sample (Abs. T) against 
the blank. 
System parameters: 
Reaction  :  End point   Sample volume: 0.02ml 
Wave length  : 520nm   Reagent volume: 1.00ml 
Materials and Methods 
 
Institute of Pharmacology, MMC Page 59 
 
Zero setting  : Reagent Blank  Reaction slope   : Increasing 
Incubator. Temp : 37oc/ room temp.  Linearity   : 20mg/dl 
Incubation time : 5 min / 15 min  Unit    : mg/dl 
Standard  : 8mg/ dl  
Calculation: 
Abs. T 
Urea in mg/ dl  = ----------------------- X 8 
     Abs. S  
ESTIMATION OF CREATININE IN SERUM 
CREATININE KIT (Alkaline Picrate method) 
Creatinine is the catabolic product of creatinine phosphate which is used by the 
skeletal muscle. The daily production depends on muscular mass and it is excreted out by the 
body entirely by the kidneys. Elevated levels are found in renal dysfunction, reduced renal 
blood flow (shock, dehydration, congestive heart failure), diabetes acromegaly. Decreased 
levels are found in muscular dystrophy. 
Principle: 
Picric acid in an alkaline medium reacts with creatinine to form a coloured complex with the 
alkaline picrate. Intensity of the colour formed is directly proportional to the amount of 
creatinine present in the sample. 
Creatinin + Alkaline picrate ----------------- Orange Red Coloured Complex 
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Contents:    15 tests  35 tests  70 tests 
L1: Picric acid reagent   60ml   140ml   2 x140ml 
L2: Buffer reagent 75ml  5ml   12ml   25ml 
S: Creatinine standard (40mg/dl) 5ml              5ml              10ml 
Storage/ stability: 
 All reagents are stable at room temperature till the expiry mentioned on the label. 
Reagent preparation: 
Reagents are ready to use. Do not pipette with mouth. 
Sample material: 
 Serum. Creatinine is stable in serum for 1 day at 2-8oc. 
Procedure: 
Wavelength/ filter : 520nm / Green 
Temperature  : Room temperature 
Light path  : 1cm 
Deproteinization of specimen: 
 Pipette into a clean dry test tube 
Picric acid reagent (L1) 
 
2.0ml 
 
Sample 0.2ml 
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Pipette into clean dry test tubes labeled as Blank (B), Standard (S) and Test (T). 
 
Addition sequence 
 
 
Blank (B) ml 
 
Standard (S) ml 
 
Test (T) ml 
Supernatant 
Picric acid reagent (L1) 
Distilled water 
Creatinine standard (S) 
Sample 
- 
1.0 
0.1 
- 
- 
- 
1.0 
- 
0.1 
- 
1.0 
- 
- 
- 
0.1 
 
Mix well and keep the test tubes at room temperature for exactly 20min. Measure the 
absorbance of the standard (Abs. S) and Test sample (Abs. T) against the blank. 
System parameters: 
Reaction  : End point   Sample volume: 0.1ml 
Wave length  : 520nm   Reagent volume: 1.1ml 
Zero setting  : Reagent Blank  Reaction slope   : Increasing 
Incubator. Temp : Room temp   Linearity   : 8mg/ dl 
Incubation time : 20min   Units    : mg/ dl 
Standard  : 8mg/ dl 
Calculation: 
 Creatinine in mg %  = Abs. T / Abs. S x 2 
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ESTIMATION OF SGOT IN SERUM54 
IFCC METHOD, KINETIC 
 The aminotransferases (transaminases) are widely distributed in animal tissues. Both 
AST and ALT are normally present in human plasma, bile, cerebrospinal fluid and saliva. 
Elevated AST levels are observed in viral hepatitis and other liver disease, cirrhosis, 
myocardial infarction. 
Principle: 
         AST 
 L- Aspartate+ 2-Oxoglutarate   Oxoloacetate + L-Glutumate 
      MDH 
 Oxoloacetate + NADH        Malate + NAD  
       LDH 
 Pyruvate + NADH   L-Lactate + NAD 
 
AST: Aspartate aminotransferase 
MDH: Malate dehydrogenase 
LDH: Lactate dehydrogenase 
KIT COMPONENTS 
1. R1- SGOT Reagent 1 
 
2. R2- SGOT Reagent 2 
 
Composition in the test: Tris buffer 80mmol/ l pH 7.8 
        L- aspartate 200mmol/ l 
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        2- Oxoglutarate 12mmol/ l 
        NADH   0.18mmol/ l 
        MDH     > 600 U/ l 
        LDH     > 900 U/ l 
        Stabilizers. 
Reagent preparation, storage and stability: 
Mix reagent 1& reagent 2 in ratio 4:1. Keep away from direct light sources. 
Stability: up to expiration date on label at 2-8oc. 
Stability of working reagent: 30days at 2-8oc. 
Reagent deterioration: 
 Discard the working reagent if absorbance < 0.8 at 340nm against distilled water. 
Specimen: 
 Use serum, plasma. SGOT is stable for 4days at 2-8oc or 1 month at -20oc. 
Test procedure: 
    
Dispense in tube: working reagent 1000 micro litre 
Add sample 50 micro litre 
Mix and incubate 60 seconds at 37oc, then record first reading of 
absorbance. Perform other readings at 60 seconds intervals. 
Calculate the ∆A/ min. 
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System parameters 
Reading mode  Rate   Volume     500 micro liter 
Factor   3376   Delay time     60sec 
Wave length  340nm   Read time     180sec 
Temperature  37oc   Unit      U/ l 
Reaction direction Decrease  Reference Low    0 
Linearity Limit 1000   Reference High    45 
Result calculation 
Perform calculations in units per litre, multiplying the ∆A/ min by the factor. 
Activity in U/ l = ∆A/ min x 3376 
  
ESTIMATION OF ALKALINE PHOSPHATASE IN SERUM53 
Modified IFCC, Kinetic: 
 Alkaline phosphatase occurs high levels in liver, bone, intestine and placenta. 
Increased levels occur in hepatobiliary diseases and bone diseases. Elevated ALP occurs in 
pregnant women and growing children. 
Principle: 
 The enzyme Alkaline phosphatase hydrolizes the 4- Nitro phenol phosphate to release 
4-nitrophenol, under alkaline conditions. The 4- Nitro phenol formed is detected 
spectrophotometrically at 405 nm to give a measurement of alkaline phosphatase activity in 
the sample. 
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 2- amino-2-methyl-1-propanol + p- nitrophenylphosphate + H2O 
          ALP 
 4 –nitrophenol + 2-amino-2-methyl-1-propanol phosphate 
Kit components 
Composition: 
Alkaline phosphatase reagent: 2- amino-2-methyl-1-propanol buffer 0.35 mol/ l –ph 10.40 
     Magnesium acetate 2mmol/ l 
     Zinc sulfate 1mmol/ l 
     HEDTA 2mmol/ l 
 4- NPP 16mmol/ l 
Reagent preparation, storage and stability: 
 Reagent is ready to use. Keep away from direct light sources. 
 Stability: up to expiration date on label at 2-8oc. 
 Stability since first opening of bottle at 2-8oc. 
Test procedure: 
Dispensing reagent in tube 1ml 
Sample 0.02ml 
 
Mix and execute a first reading of absorbance after 1minute, incubating at 37oc. Perform 
other 2 readings at 60seconds intervals. Calculate the ∆A/ min. 
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System parameters: 
Reading mode  End point  Sample Volume  20 micro liter 
Factor   2764   Wave length  405nm 
 Temperature  37oc   Unit   U /l 
Reagent volume 1ml   Reference Low  42 
Linearity Limit 1200   Reference High  128 
Calculation: 
 Alkaline phosphatase U/ l = ∆A/ min x 2764 
LACTATE DEHYDROGENASE (LDH) ASSAY52,62 
Principle 
 The assay was performed according to King’s et al., (1965) method, when the enzyme 
is supplied with Pyruvate and NADH+, the LDH catalyzed reaction starts to produce lactate. 
At certain time point the reaction is terminated by the addition of 2,4- 
dinitrophenylhydrazine, which reacts with lactate at acidic pH
.  
After alkalization (addition of 
NaOH) the resulting hydrazine derivate gives a yellowish-orange colour suitable for 
quantification by means of spectrophotometry at the wavelength of 440 nm. 
Requirements 
 0.1M phosphate buffer (pH 7.5) 
 NADH(6.6 mM) 
 Sodium pyruvate (30mM) 
 Dinitro phenyl hydrazine 
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Procedure 
 0.1ml of tissue homogenate was added with 2.7ml buffer, 0.1ml NADH and 0.1ml 
sodium pyruvate. The mixture was heated for 15mins at 37°C. Then 0.5ml of dinitro phenyl 
hydrazine was added and incubated at room temperature for 15mins. The reaction was 
stopped by addition of 5ml 0.1N NaOH. The developed colour was measured at 440nm. 
 
LYSOSOMAL ENZYMES ESTIMATION IN TISSUE PREPARATIONS 
ASSAY OF ALKALINE PHOSPHATASE (ALP)61 
Principle 
 When the enzyme incubated with p-nitro phenyl phosphate and Tris buffer (pH 9.6), in 
alkaline condition inorganic phosphate and p-nitro phenol are formed by the catalytic action 
of alkaline phosphatase. Amount of p-nitro phenol liberated by the enzyme is measured at 
420 nm. 
2-amino-methyl-1-propanol + p-nitro phenyl phosphate + H2O 
 
 
4-nitro phenol + 2-amino-2-methyl-1-propanol phosphate 
Requirements 
 P-nitro phenyl phosphate (10 mM) 
 Tris-HCl pH 9.6 (80mM) 
 NaOH (0.1N) 
Procedure 
 1ml of p-nitro phenyl phosphate and 1.5ml of buffer were added with 100µl of 
homogenate. The mixture was incubated at 37°C for 30mins. Then the reaction was stopped 
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by addition of 0.1 N NaOH. The absorbance of liberated p-nitro phenol was measured at 
420nm. 
Calculation  
 ALP U/I = ∆A/ 2764 
ASSAY OF ACID PHOSPHATASE (ACP)60 
(α-Naphthylphosphate Kinetic method) 
Principle 
 In acidic condition, the incubation of α-Naphthylphosphate with ACP will liberate α –
Naphthol and inorganic phosphate due to catalytic action of ACP. The –Naphthol formed is 
coupled with Fast Red to form a diazo dye complex. The rate of formation of this complex is 
measured as an increase in absorbance which is proportional to the ACP activity in the 
sample. 
α –Naphtholphosphate + H2O  ACP  α –Naphthol + Phosphate 
α –Naphthol + Fast Red TR Sal   Diazo dye complex 
Requirements 
 α –Naphthol phosphate (4.5mM) 
 acetate buffer (pH 5.0) 
 NaOH (0.2N) 
Procedure 
 1ml of α –Naphthol and 1.9 ml of buffer were added with 100µl of homogenate. The 
mixture was incubated at 37°C for 30mins. The absorbance of liberated α –Naphthol was 
measured at 420 nm. 
Calculation  
 ACP activity in U/L = ∆A/min x 750 
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ESTIMATION OF ASPARTATE AMINOTRANSFERASE (AST/ SGOT)59 
 Aspartate transaminase (AST) also referred to serum glutamate oxaloacetate 
transferase (SGOT) is an enzyme involved in amino acid metabolism. AST is widely 
distributed in liver, RBCs, heart, pancreas and kidney. A low level of SGOT in blood is 
observed in severe liver disease, myocardial infarction, heart failure, kidney disease and lung 
disease. 
Principle 
 α-Ketoglutarate + L-Aspartate SGOT  L-Glutamate + Oxaloacetate 
 Oxaloacetate + NADH+ H+  MDH  L-Malate + NAD+ 
 The rate of NADH consumption is measured photometrically and is directly 
proportional to the SGOT concentration in the sample. 
 
Reagents  
 L-Aspartate  >200mmol/l 
 Malate dehydrogenase > 200mmol/l 
 α-Ketoglutarate>35mmol/l 
 NADH >1.05 mmol/l 
Procedure 
 800µl of L-Aspartate & Malate dehydrogenase and 200µl of α-Ketoglutarate are 
mixed together and incubated at 37°C for 2minutes and 100µl of sample is added. The 
change in absorbance is measured at 340nm. 
Calculation 
AST = ∆ Abs/ min  x Factor (1746) 
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ESTIMATION OF ALANINE AMINOTRANSFERASE (ALT/ SGPT)58 
Alanine aminotransferase /  serum glutamate pyruvate transferase ia an enzyme involved in 
amino acid metabolism. 
Principle 
 α-Ketoglutarate + L-Alanine SGPT  L-Glutamate + Pyruvate 
 Pyruvate + NADH+ H+  LDH  L-Lactate + NAD+ 
 The rate of NADH consumption is measured photo metrically and is directly 
proportional to the SGPT concentration in the sample. 
Reagents  
 L-Alanine  >200mmol/l 
 Lactate dehydrogenase > 1500mmol/l 
 α-Ketoglutarate>35mmol/l 
 NADH >1.05 mmol/l 
 Tris buffer 80mmol/l pH 7.5 
Procedure 
 800µl of L-Alanine & Lactate dehydrogenase and 200µl of α-Ketoglutarate are mixed 
together and incubated at 37°C for 2minutes and 100µl of sample is added. The change in 
absorbance is measured at 340nm. 
Calculation 
ALT = ∆ Abs / min  x Factor (1746) 
III) HISTOPATHOLOGICAL ASSAY31,63 
 At the 29th day, one rat from each group was sacrificed and both kidneys of each rat 
were removed for histopathologic examination. Removed kidneys were fixed in 10 % 
buffered formalin (MERK) over night and then each was sliced longitudinally in 3 sections, 
including anterior, middle and posterior parts of the kidney. Thereafter, they were 
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automatically processed and inserted in paraffin blocks and at least 6 sections with 5 micron 
thickness were obtained from each kidney and stained by Hematoxylin and Eosin. 
IV) Statistical analysis31 
 Results were expressed as mean ± S.D. Differences among data were determined 
using one-way ANOVA followed by Dunnet’s test. Differences between the data were 
considered significant at p< 0.05. 
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5. RESULTS AND DISCUSSION 
PRELIMINARY PHYTOCHEMICAL ANALYSIS 
   
TEST 
 
Ethanol 
         Ext. 
Ethyl acetate 
Ext. 
Chloroform 
Ext. 
Pet.ether 
Ext. 
1.TEST FOR FLAVONOIDS 
a) Shinado’s test 
b) Sodium hydroxide test 
+ + + + 
2.TEST FOR TANNINS 
         With lead acetate 
+ + - - 
3.TEST FOR SAPONINS 
           Foam test 
 
+ 
 
+ 
 
 
- - 
4.TEST FOR TERPENOIDS 
            With Tin and thionyl 
chloride 
+ + - - 
5.TEST FOR GLYCOSIDES 
a) Libermann-burchard’s 
test 
b) Legal’s test 
c) Borntrager’s test 
- - - - 
6.TEST FOR 
PHYTOSTEROLS 
           Libermann test 
+ + + + 
7.TEST FOR  MUCILAGE 
          Swelling test 
- - - - 
8.TEST FOR PROTEIN 
a) Biuret test 
b) Million’s test 
+ + + + 
9.TEST FOR 
CARBOHYDRATES 
          Molish’s test 
+ + + - 
Results and Discussion 
 
Institute of Pharmacology, MMC Page 73 
 
10.TEST FOR ALKALOIDS 
a) Drangendroff’s test 
b) Mayer’s test 
c) Hager’s test 
d) Wagner’s test 
+ + + - 
 
 (+present)  (-absent) 
Table 5.1Preliminary phytochemical analysis of various extract of Azima tetracantha 
Lam. 
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5.1 INVITRO ANTIUROLITHIATIC ACTIVITY: 
CALCIUM OXALATE CRYSTALLIZATION INHIBITION BY VARIOUS 
EXTRACT OF WHOLE PLANT OF Azima tetracantha Lam. 
 The effect of various extract of plant extract on various phases of calcium oxalate 
crystallization was determined by time course measurement of turbidity in the sodium 
chloride solution. The absorbance according to the time for tries without and with inhibitor 
was represented in the graph taking time vs. absorbance. The values of the change in 
absorbance for all the extract were noted and a graph was plotted. 
    Table 5.2 Calcium oxalate crystallization inhibition with the formulation 
S.No Time in Secs Without 
Inhibitor 
Ethanol Ethyl 
acetate 
Chloroform Pet.ether 
1 30 0.16 0.04 0.09 0.10 0.14 
2 60 0.22 0.17 0.25 0.38 0.40 
3 90 0.45 0.19 0.35 0.40 0.42 
4 120 0.72 0.21 0.39 0.50 0.65 
5 150 0.82 0.25 0.45 0.58 0.72 
6 180 0.93 0.29 0.56 0.66 0.76 
7 210 0.97 0.33 0.60 0.68 0.80 
8 240 0.99 0.35 0.62 0.68 0.82 
9 270 0.99 0.35 0.62 0.70 0.82 
10 300 0.99 0.35 0.62 0.70 0.82 
11 330 0.99 0.35 0.62 0.70 0.82 
12 360 0.99 0.35 0.62 0.70 0.82 
13 390 0.99 0.35 0.62 0.70 0.82 
14 420 0.99 0.35 0.62 0.70 0.82 
15 450 0.99 0.35 0.62 0.70 0.82 
16 480 0.99 0.35 0.62 0.70 0.82 
17 510 0.99 0.35 0.62 0.70 0.82 
18 540 0.99 0.35 0.62 0.70 0.82 
19 570 0.99 0.35 0.62 0.70 0.82 
20 600 0.99 0.35 0.62 0.70 0.82 
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Fig 5.1 Calcium oxalate crystallization inhibition with plant extract 
 The graph shows an initial detectable increase in the turbidity after induction of the 
crystallization with sodium oxalate, was observed. In the control experiment, there was an 
initial steep rise in turbidity (the nucleation phase), on attaining its maximum, it was followed 
by a decrease (the aggregation phase).  
 The various plant extract, inhibited the slope of turbidity followed by very slow 
decrease in graph. Crystallization was inhibited significantly with ethanolic plant extract 
followed by ethyl acetate, chloroform and petroleum ether plant extract. 
 The linear proportion of the graph was taken up for detecting the slope. 
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   Fig 5.2 Linear portion of the graph 
MICROSCOPIC STUDY: 
 The ethanolic plant extract on being examined under the microscope show that the 
ethanolic plant extract had decreased the number of crystals. The first photograph 
corresponding to the stages of the growth and aggregation for the crystallization without 
inhibitor of calcium oxalate. The comparison of photographs (II,III,IV and V) of the tries 
with inhibitor (ethanolic extract) enabled us to understand that crystals were greatly reduced 
in number, which explains that the ethanolic extract produces significant quantity of 
inhibition on growth of the crystal. 
S.No Extracts % Inhibition 
1. Ethanolic extract 82% 
2. Ethyl acetate extract 75% 
3. Chloroform extract 66% 
4. Pet. ether extract 55% 
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I  Control 
II, III, IV With Inhibitor solution in time dependent manner shows decrease in 
crystal number after 10min, 20 min, 30 min 
             Fig 5.3 Microscopic photographs of calcium oxalate crystallization inhibition 
 The photograph clearly indicates that in case where the ethanolic plant extract was not 
added, the number of crystals is maximum (photo I). In the photographs II, III and IV which 
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represent the crystal formation when the solution was mixed with plant extract , there was a 
clear indication that there is a dose dependent manner of crystals formed and with time. 
 Kidney oxalate stone is the result of super saturation of urine with certain urinary salts 
such as calcium oxalate. Since crystallizable oxalate species are pH dependent, the 
crystallization of oxalate in the absence of an inhibitor, led to the formation of calcium 
oxalate monohydrate monitored by light microscope, the process of calcium oxalate 
crystallization in control without the addition of inhibitors is shown in (Figure I). 
 In the crystal growth experiments shown nucleation, growth and aggregation, the rate 
of crystallization is usually controlled by the number of crystals of calcium oxalate as a 
function of time, following the introduction of seed crystals. Entitled constant volume against 
time in the composition calcium oxalate experiments determined that the rate of growth of 
crystals were made in the absence and presence of ethanolic plant extract. 
 In order to assess the inhibiting potential of substances for oxalate crystallization and 
understand the mechanisms of action of these inhibitors on oxalate crystallization steps viz. 
nucleation, growth, aggregation, we tested the effectiveness of ethanolic plant extract. 
5.2 IN-VIVO ANTIUROLITHIATIC ACTIVITY OF VARIOUS EXTRACT OF 
WHOLE PLANT OF Azima tetracantha Lam. ON ETHYLENE GLYCOL INDUCED 
IN RATS 
 From the acute toxicity study, the LD50 cut-off dose was found to be 2000 mg/kg body 
weight for the plant Azima tetracantha Lam. Hence the therapeutic dose was taken as 200 
mg/kg/b.w. for the plant.  
 Ethylene glycol (EG) is rapidly absorbed and metabolized in the liver via alcohol 
dehydrogenase/ aldehyde dehydrogenase to glycolic acid. Glycolic acid is oxidized to 
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glycolate, which, in turn, is further oxidized to oxalic acid by glycolate oxidase. High doses 
of EG (>2,500 mg/kg body wt.), particularly when given as an oral bolus, cause the saturation 
dependent accumulation of glycolic acid in the plasma so glycolate oxidase (GO) is one of 
the rate limiting enzymes in the metabolism of EG (Green et al.,2005). 
   Table5.2Estimation of urine volume 
                               Group 
 
    Volume of urine(ml) 
Control 
 
2.08±0.15 
Induced (Ethylene glycol 0.75%) 
 
1.18±0.14 
Standard (Cystone 750mg/kg) 
 
2.5±0.14 
Ethanolic plant extract (200mg/kg) 
 
2.1±0.13 
Ethyl acetate plant extract (200mg/kg) 
 
2.06±0.13 
Chloroform plant extract (200mg/kg) 
 
1.9±0.17 
Pet.ether plant extract (200mg/kg) 
 
1.16±0.18 
  The values are expressed as Mean ± SD, n=6. 
*P < 0.05 as compared to control. 
                   
    Fig 5.4 Estimation of Urine Volume 
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 The glomerular filtration rate (GFR) is an important parameter for ensuring renal 
function and it gets decreased in urolithiasis due to the obstruction to the outflow of the urine 
by stones in urinary system, 
 Which leads to a rise in nitrogenous waste products like urea, creatinine and uric acid 
in blood. 
Table 5.3 pH of Urine 
                               Group 
 
pH 
Control 
 
7.1 ± 0.16 
Induced (Ethylene glycol 0.75%v/v) 
 
6.51 ± 0.24 
Standard (Cystone 750mg/kg) 
 
7.5 ± 0.08 
Ethanolic plant extract (200mg/kg) 
 
7.15 ± 0.16 
Ethyl acetate plant extract (200mg/kg) 
 
7.0 ± 0.08 
Chloroform plant extract (200mg/kg) 
 
7.0 ± 0.08 
Pet.ether plant extract (200mg/kg) 
 
6.85 ± 0.05 
  
The values are expressed as Mean ± SD, n=6. 
*P < 0.05 as compared to control. 
 
         Fig 5.5 Estimation of Urine pH 
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Urinary pH of control is neutral, ethylene glycol induced rats pH is reduced compared 
with control group. Treatment with (Cystone 750 mg/kg) was found to increase the urine pH 
(7.5±0.08), whereas, groups receiving plant extract also found to increase the urinary pH in a 
dose dependent manner but ethanol and ethyl acetate plant extract produces significant 
increase in pH nearly to that of control (p<0.05). 
Table 5.4 Estimation of calcium, magnesium, phosphorous and Oxalate 
Group 
 
Calcium 
    (mg/dl) 
Magnesium 
   (mg/dl) 
Oxalate 
    (mg/dl) 
Phosphorus 
   (mg/dl) 
Control 
 
8.56 ± 0.19 2.63 ± 0.08 1.36 ± 0.10 5.36 ± 0.10 
Induced(Ethylene glycol 0.75%v/v) 11.6 ± 0.34 1.33 ± 0.12 5.5 ± 0.37 7.71 ± 0.17 
Standard (Cystone 750mg/kg)  8.88 ±0.07 2.66 ± 0.22 1.44 ± 0.08 5.86 ± 0.05 
Ethanolic plant extract (200mg/kg) 8.53 ± 0.13 2.66 ± 0.16 1.63 ± 0.08 5.46 ± 0.12 
Ethyl acetate plant extract (200mg/kg) 
 
8.7 ± 0.20 2.4 ± 0.23 1.88 ± 0.07 5.95 ± 0.25 
Chloroform plant extract (200mg/kg) 
 
9.06 ± 0.12 2.21 ± 0.17 2.43 ± 0.17 6.1 ± 0.24 
Pet.ether plant extract (200mg/kg) 10.11 ± 0.48 1.76 ± 0.16 2.71 ± 0.11 6.7 ± 0.31 
 
The values are expressed as Mean ± SD, n=6. 
*P < 0.05 as compared to control. 
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  Fig 5.6 Estimation of Ca,PO4, Mg and Oxalate 
Formation of calculi is associated with super saturation of urine with stone forming 
constituents. Repeated administration of ethylene glycol (0.75%v/v) cause generation of 
kidney stone and the most important cause for it was found to be presence of calcium oxalate. 
Increase in the urinary concentration of oxalate is considered as one of the major cause 
responsible for formation of stone. Stone formation in ethylene glycol administered animals 
is caused by hyperoxaluria, which enhances renal retention and excretion of oxalate50. In this 
study it was observed that ethanol and ethyl acetate plant extract (200mg/kg) significantly 
decreased level of oxalate, calcium, phosphate and increased the level of magnesium in urine. 
The urine mineral constituents-calcium, magnesium, oxalate and phosphorus in 
control and experimental rats. Calcium, oxalate and phosphorus play a vital role in renal 
calculogenesis. In the present study, chronic administration of 0.75% v/v ethylene glycol 
aqueous solution for 28 days resulted in hypercalciuria in rats64. Phosphorus, oxalate and 
calcium excretion were significantly increased (p<0.05), whereas magnesium decreased in 
urine and kidney of EG treated animals group II as compared to group I. 
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 However, supplementation with plant extracts at 200 mg/kg body weight and cystone 
750 mg/kg body weight significantly (P < 0.05) lowered the elevated level of phosphorus and 
calcium in urine as compared to the group II animals. 
 Magnesium level in the standard and test groups came close to normal and was 
comparable to the levels in the belonging to the untreated group II. 
 However among the four plant extracts the ethanolic plant extract and ethyl acetate 
plant extract produces significant effect. 
   Table 5.5 Estimation of serum constituents 
Group 
 
Urea(mg/dl) Uric acid(mg/dl) 
Control 
 
9.9 ± 0.07 2.21 ± 0.17 
Induced (Ethylene glycol 0.75% v/v) 
 
15.73 ± 0.18 4.78 ± 0.22 
Standard (Cystone 750mg/kg) 
 
10.15 ± 0.09 2.33 ± 0.19 
Ethanolic plant extract (200mg/kg) 
 
9.81 ± 0.16 2.43 ± 0.13 
Ethyl acetate plant extract (200mg/kg) 
 
10.4 ± 0.10 2.73 ± 0.19 
Chloroform plant extract (200mg/kg) 
 
10.86 ± 0.05 3.05 ± 0.12 
Pet.ether plant extract (200mg/kg) 
 
11.28 ± 0.14 3.46 ± 0.13 
   
The values are expressed as Mean ± SD, n=6. 
*P < 0.05 as compared to control 
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Fig 5.7 Estimation of Urea and Uric acid 
 
Table 5.6 Estimation of creatinine and BUN 
Group 
 
Creatinine(mg/dl) BUN(mg/dl) 
Control 
 
0.38 ± 0.02 4.70 ± 0.05 
Induced (Ethylene glycol 0.75%v/v) 
 
0.64 ± 0.03 7.5 ± 0.15 
Standard (Cystone 750mg/kg) 
 
0.42 ± 0.04 4.79 ± 0.21 
Ethanolic plant extract (200mg/kg) 
 
0.42 ± 0.03 4.61 ± 0.09 
Ethyl acetate plant extract (200mg/kg) 
 
0.48 ± 0.05 4.93 ± 0.18 
Chloroform plant extract (200mg/kg) 
 
0.51 ± 0.02 4.98 ± 0.20 
Pet.ether plant extract (200mg/kg) 
 
0.58 ± 0.04 5.47 ± 0.15 
 
 The values are expressed as Mean ± SD, n=6. 
*P < 0.05 as compared to control 
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    Fig 5.8 Estimation of creatinine and BUN 
 Decrease in glomerular filtration due to obstruction generated in the kidney cause 
accumulation of waste products in blood, thus level of waste components like BUN, uric 
acid, urea and creatinine increases in blood. 
In calculi-induced rats (Group II), marked renal damage was seen by the elevated 
serum levels of creatinine, uric acid, urea and Blood Urea Nitrogen (BUN)50. However, 
treatment with plant extract restored the serum levels of creatinine, uric acid and BUN. 
 The ethanolic and ethyl acetate plant extract (Group IV and V) and Cystone (Group 
III) significantly (p<0.05) lowered the elevated serum level uric acid as compared to group I.  
Chloroform and pet.ether extract also decreased the level of urea, uric acid, creatinine and 
BUN level in the serum of urolithiatic induced rats. 
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Table 5.7 Estimation of ACP, AST, ALP and ALT in serum 
Group 
 
 
ACP 
(U/ml) 
AST 
(U/ml) 
ALP 
(U/ml) 
ALT 
(U/ml) 
Control 
 
66.6 ± 1.36 32.6 ± 1.63 73.3 ± 1.63 31 ± 0.89 
Induced (Ethylene glycol 0.75%) 
 
113.8 ± 3.06 87.5 ± 4.32 153.6 ± 2.8 95.1 ± 0.75 
Standard (Cystone 750mg/kg) 
 
73 ± 1.67 37.1 ± 1.60 75.6 ± 1.96 32.6 ± 2.06 
Ethanolic plant extract 
(200mg/kg) 
 
71.6 ± 2.73 37.8 ± 1.32 76 ± 2.52 35 ± 1.41 
Ethyl acetate plant extract 
(200mg/kg) 
 
77 ± 2.09 40.3 ± 1.36 79.6 ± 1.50 42.1 ± 2.22 
Chloroform plant extract 
(200mg/kg) 
 
81 ± 0.89 43.6 ± 1.50 88.3 ± 1.50 41.8 ± 1.72 
Pet.ether plant extract 
(200mg/kg) 
 
87.1 ± 2.78 51.8 ± 2.31 98 ± 1.78 50.8 ± 3.48 
 
The values are expressed as Mean ± SD, n=6. 
*P < 0.05 as compared to control. 
From the table it was evident that the levels of the enzymes like ACP, AST, ALP and 
ALT were significantly increased (p<0.05) in serum of ethylene glycol intoxicated (group II) 
rats64. In the ethanolic (group IV) and ethyl acetate (group V) plant extract treated groups the 
enzymes level were decreased significantly in the serum when compared to group II rats. As 
the evident from the above results, the ethanolic and ethyl acetate extract of Azima 
tetracantha Lam. seems to contain antiurolithiatic activity. However, when the standard drug, 
Cystone treated rats (group III) were compared with plant extract treated rats (group IV&V), 
there is no significant difference (p<0.05) was observed. 
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                    Fig 5.9 Estimation of ACP, AST, ALP and ALT in serum 
Table 5.8 Estimation of ACP, AST, ALP and ALT in kidney 
Group ACP AST ALP ALT 
Control 
 
12.5 ± 0.87 11.7 ± 0.70 6.66 ± 0.51 13.01 ± 0.33 
Induced (Ethylene glycol 
0.75%v/v) 
 
8.5 ± 0.44 6.78 ± 0.51 3.5 ± 0.35 9.48 ± 0.33 
Standard (Cystone 750mg/kg) 
 
13.2 ± 0.87 12 ± 0.89 6.67 ± 0.24 12.83 ± 0.26 
Ethanolic plant extract 
(200mg/kg) 
 
13.1 ± 0.83 11.9 ± 0.93 6.51 ± 0.31 12.81 ± 0.26 
Ethyl acetate plant extract 
(200mg/kg) 
 
11.3 ± 0.85 10.6 ± 0.45 6.15 ± 0.28 11.9 ± 0.08 
Chloroform plant extract 
(200mg/kg) 
 
10.6 ± 0.58 9.7 ± 0.38 5.5 ± 0.32 11.3 ± 0.32 
Pet.ether plant extract (200mg/kg) 
 
9.8 ± 0.68 8.66 ± 0.40 4.8 ± 0.20 10.73 ± 0.47 
The values are expressed as Mean ± SD, n=6. 
*P < 0.05 as compared to control. 
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Units: 
ALP, ACP -µ moles of phenol liberated/min./mg of protein 
AST, ALT - µ moles of pyruvate liberated/min./mg of protein 
LDH - µ moles of pyruvate liberated/L 
From the table it was evident that the levels of the enzymes like ACP, AST, ALP and 
ALT were significantly decreased (p<0.05) in kidney of ethylene glycol intoxicated (group 
II) rats64. In the ethanolic (group IV) and ethyl acetate (group V) plant extract treated groups 
the enzymes level were increased significantly in the serum when compared to group II rats. 
As the evident from the above results, the ethanolic and ethyl acetate extract of Azima 
tetracantha Lam. seems to contain antiurolithiatic activity. Chloroform and Pet. Ether extract 
also produces anti-urolithiatic activity but not as much as ethanol and ethyl acetate extract. 
However, when the standard drug, Cystone treated rats (group III) were compared with plant 
extract treated rats (group IV&V), there is no significant difference (p<0.05) was observed. 
 
 
  Fig 5.10 Estimation of ACP, SGOT, ALP and SGPT in kidney 
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Table 5.9 Estimation of LDH in Serum and Kidney 
Group 
 
LDH in Serum 
(µmoles/L) 
LDH in Kidney     
(U/mg) 
Control 
 
145.9 ± 0.70 3.71 ± 0.02 
Induced (Ethylene glycol 0.75%) 
 
205.4 ± 0.49 7.58 ± 0.07 
Standard (Cystone 750 
mg/kg) 
 
146.8 ± ± 0.67 3.77 ± 0.02 
Ethanolic plant extract (200 mg/kg) 
 
147.9 ± 0.50 3.74 ± 0.03 
Ethyl acetate plant extract (200 mg/kg) 
 
 
152 ± 0.40 4.18 ± 0.11 
Chloroform plant extract (200 mg/kg) 
 
 
154.5 ± 0.8  4.5 ± 0.12 
Pet.ether plant extract (200mg/kg) 
 
 
160.75 ± 0.27 4.9 ± 0.16 
 
The values are as Mean ± SD, n=6. 
*P < 0.05 as compared to control. 
 
The above table represents the levels of lactate dehydrogenase levels in the serum and 
kidney homogenate. Level of LDH was significantly increased in serum and kidney 
homogenate of ethylene glycol intoxicated (group II) rats. LDH is an oxalate synthesizing 
enzyme; its activity was increased on ethylene glycol administration65. It was released into 
the blood stream and urine. This may be attributed to oxalate induced renal and hepatic 
cellular damage. Renal damage is particularly confined to the proximal tubule, a part of the 
nephron closely involved in handling urinary oxalate. The treatment (groups IV&V) with 
ethanolic and ethyl acetate plant extract after ethylene glycol induction showed a significant 
(p<0.05) decrease in the activity of these enzymes in serum and tissue homogenate when 
compared to group II rats. As evident from above results, the plant Azima tetracantha Lam. 
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seems to contain antiurolithiatic activity. However, when the standard drug, Cystone treated 
rats (group III) were compared with plant extract administered group (group IV&V), no 
significant difference (p<0.05) was observed between these three groups of animals. 
HISTOPATHOLOGICAL EXAMINATION OF THE RAT KIDNEYS 
 The present histopathological studies showed EG exposed urolithiatic rats showed 
deposition of calcium oxalate crystals in lumen of Proximal convoluted tubule Figure-1. 
Tubules were highly dilated and cystic with sloughing off the tubular epithelial cells. While 
in plant extract treated animals, it apparently retained normal morphological and 
microscopical anatomical architecture of the nephrons. However, mild degeneration of cells 
and cyst formation was observed. 
 
 
 
 
 
Group I: Control rat Group II: Ethylene glycol induced rat  
Results and Discussion 
 
Institute of Pharmacology, MMC Page 91 
 
 
 
                           
 
 
 
 
 
 
  
    Group V: Ethyl acetate extract treated rat 
   Group VI: Chloroform extract treated rat 
    Group IV: Ethanolic extract treated rat  
     Group III: Standard Cystone treated rat 
Group VII: Pet. Ether extract treated rat 
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The antiurolithiatic effect was further confirmed by kidney histopathological studies. 
Indeed, kidney sections of untreated rat showed abundant crystal depositions. Furthermore, 
renal epithelial cells had more tubular dilatation and damage shown by large spaces in the 
tissue. In treated rats, less crystal depositions were seen compared to untreated animals and 
the necrosis as well as the tubule dilatation was very limited. Renal stone deposition damages 
the renal tissue and detoriate the renal function. Lithogenic treatment caused impairment of 
renal functions of the untreated rats as evident from the markers of glomerular and tubular 
damage: raised BUN, uric acid, urea and serum creatinine that was lowered in animals 
receiving plant extract. 
 Tissue injury and inflammation in these animals is due to exposure to phosphate and 
calcium phosphate crystals, leading to the generation of reactive oxygen species, 
development of oxidative stress, lipid peroxidation and depletion of antioxidant enzymes. 
Renal epithelial injury further promotes crystal retention, as epithelial injury exposes a 
variety of crystal adhesion molecules on epithelial surfaces and promotes stone formation. 
Probably antioxidant constituents of the plant restore the renal antioxidant enzyme and 
prevent renal cell injury. 
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CONCLUSION 
 
 From the present study we conclude that the preliminary phytochemical analysis of 
Azima tetracantha Lam. indicated the presence of Alkaloids, Flavonoids, Proteins, 
Saponins, Terpenoids, Phytosterols, Carbohydrates and Fatty acids. 
 In-vitro Calcium oxalate crystallization inhibition study was evaluated. From this 
study we conclude that the ethanol, ethyl acetate, chloroform and pet.ether extracts of 
Azima tetracantha Lam. inhibits the calcium oxalate crystallization in the order of 
82%, 75%,66% and 55% respectively. 
 In-vivo Anti urolithiatic activity of various extracts (Ethanol, Ethyl acetate, Chloroform and 
Pet.ether) of Azima tetracantha Lam. was evaluated and we conclude that the ethanol 
and ethyl acetate extracts of the plant Azima tetracantha Lam. produced significant  
antiurolithiatic activity like that of standard. Moderate effect was produced by 
chloroform extract.  
 
 
                               LIST OF ABBREVIATIONS 
 
WHO    -- World Health Organisation 
AT    -- Azima tetracantha Lam. 
E.coli    -- Escherichia coli 
C    -- Control 
E.G    -- Ethylene glycol 
STD    -- Standard (Cystone) 
ETH    -- Ethanol 
E.A    -- Ethyl acetate 
CHL    -- Chloroform 
P.ET    -- Petroleum ether 
Pet.ether   -- Petroleum ether 
LDH    -- Lactate dehydrogenase 
MDH    -- Malate dehydrogenase 
AST    -- Aspartate aminotransferase 
HEDTA   -- Hydroxyl Ethylethylene Diamine Triactic Acid 
NPP    -- Non-prostatic phosphatase 
NADP    -- Nicotinamide adenine dinucleotide phosphate 
CPCSEA   -- Committee for the Purpose of Control and Supervision on  
     Experiment on Animals 
ALT    -- Alanine Aminotransferase 
AST    -- Aspartate Aminotransferase 
FDA    -- Food and Drug Administration 
Rtd    -- Retired 
CSIR    -- Council for Scientific and Industrial Research 
EDTA    -- Ethylene diamine tetra acetic acid 
ATP    -- Adenosine Tri Phosphate 
NAD    -- Nicotinamide Adenine Dinucleotide 
NADH    -- Reduced Nicotinamide Adenine Dinucletide 
IAEC    -- Institutional Animal Ethical Committee 
OECD    -- Organisation for Economic Co-operation and Development 
SGOT    -- Serum Glutamate Oxaloacetic Transaminase 
SAP    -- Serum Alkaline Phosphate 
SGPT    -- Serum Glutamic Pyruvic Transaminase 
WBC    -- White Blood Cell 
H2O2    -- Hydrogn Peroxide 
H2O    -- Water 
ALP    -- Alkaline Phosphatase 
ACP    -- Acid Phosphatase 
ANOVA   -- Analysis of Variance 
SD    -- Standard Deviation 
Ppm    -- parts per million 
rpm    -- Revolutions per minute 
mins    -- Minutes 
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